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Abstract 
Growth hormone (GH) regulates energy metabolism and body composition in adult life. Adults 
with GH deficiency (GHD) suffer from lack of energy and from impaired physical functioning. GH 
supplementation improves sprinting in recreational athletes, a performance measure dependent on 
the anaerobic energy system (AES). The AES underpins the initiation of all physical activities 
including those of daily living. The physiological and functional significance of GH in regulation of 
the AES is unknown. 
 
This thesis tests the hypothesis that GH positively regulates the AES and aspects of physical 
functioning in adult life. The key objectives are to 1) investigate whether anaerobic capacity is 
impaired in adults with GHD and improved by GH replacement, ii) characterise facets of physical 
function that are AES-dependent and GH responsive and iii) identify GH-regulated genes governing 
anaerobic metabolism in skeletal muscle. 
 
Exercise capacity, body composition, physical function and quality of life (QoL) were studied in 19 
adults with GHD before and after GH replacement. Anaerobic capacity was assessed by the 30-
second Wingate test, and aerobic capacity by the VO2max test. Physical function was assessed by 
the stair-climb test, chair-stand test, and 7-day pedometry. QoL was assessed by a GHD-specific 
questionnaire. Lean body mass (LBM) was quantified by dual-energy x-ray absorptiometry. Muscle 
biopsies were obtained before and after 1 and 6 months of GH replacement. GH responsive genes 
were identified by microarray analysis.  
 
In a cross-sectional study, anaerobic capacity and aerobic capacity were significantly reduced 
compared to age-, gender- and body mass index-matched normal adults. The duration of the stair 
climb test was longer, the number of chair stand repetitions and daily step counts were lower in 
adults with GHD who had lower QoL scores. GH status was an independent predictor of anaerobic 
capacity, which significantly and independently correlated with stair climb performance and QoL. 
 
One month of GH replacement (0.5 mg/day) did not significantly change anaerobic capacity nor 
any of the other outcome measures compared to placebo in adults with GHD. Six months of GH 
treatment significantly increased LBM, anaerobic capacity, chair-stand repetitions, daily step count, 
and QoL scores but not VO2max. Improvement in anaerobic capacity significantly correlated with 
an improvement in the energy and vitality domains of QoL. GH treatment did not significantly 
affect the differential expression of metabolic genes in skeletal muscle. 
 
In summary, anaerobic capacity, aerobic capacity, physical function and QoL were impaired in 
adults with GHD. GH replacement improved anaerobic capacity, LBM, chair-stand performance, 
daily step counts and QoL in a time-dependent manner without a concomitant improvement in 
aerobic capacity. GH at a replacement dose was insufficient to induce the detection of GH-regulated 
genes governing substrate metabolism and energy production in skeletal muscle. 
 
In conclusion, GH positively regulates the AES, which improves selective aspects of physical 
function influencing QoL in adult humans. 
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1! INTRODUCTION 
 
Growth hormone (GH) is the most abundant hormone in the adult pituitary gland. It is a major 
metabolic hormone regulating carbohydrate, lipid and protein homeostasis (1). Adult-onset GH 
deficiency (GHD) is mainly caused by tumours of pituitary gland or of the hypothalamic area or by 
their treatment (i.e. surgery or irradiation) (2). It results in abnormal body composition reduced 
muscle strength and endurance capacity, and in impaired quality of life (QoL) (3).  
 
Energy derived from the metabolism of fuels is required to drive the function of all body tissues. 
The energy is derived from two metabolic pathways: aerobic (oxygen-dependent) and anaerobic 
(oxygen-independent) (4). Aerobic energy is derived from oxidative pathways in the mitochondria 
whereas anaerobic energy is available as preformed adenosine triphosphates (ATP) or ATP 
generated from glycolysis. Energy derived from aerobic metabolism is the form mainly used at rest 
and during endurance exercise. In contrast, energy drawn from anaerobic metabolism powers 
intensive physical activity of brief duration. Anaerobic energy underpins the initiation of all form of 
physical activity including activities of daily living such as climbing stairs and running for a bus 
(5). Impairment of anaerobic capacity leads to increased fatigue during the execution of ordinary 
activities of daily living, which is the most common symptom associated with GHD. The anaerobic 
energy system (AES) has been a neglected area of fitness research, which has heavily focussed on 
the aerobic energy system. 
 
Strength and power are measures of muscle function. Strength is the force producing capacity of 
muscle and it relies on preformed ATP. Power is the ability to perform muscular work per unit of 
time (i.e. work rate). Muscle power relies on either aerobic or anaerobic energy system, depending 
on the intensity and duration of work. There is strong evidence that muscle strength and aerobic 
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capacity are significantly reduced in adults with GHD and restored with GH replacement over a 
period of few months (3, 6). The question as to whether GH regulates the AES, or whether 
anaerobic capacity is impaired in GHD, has not been investigated. Evidence pointing to a regulatory 
role of anaerobic metabolism by GH comes from two recent studies, one on metabolic gene 
expression in skeletal muscle (7) and the other on physical performance (8). In patients with GHD, 
GH treatment inhibited the expression of mitochondrial genes involved in oxidative energy 
production and stimulated those governing glycolysis, the major energy generating anaerobic 
pathway (7). In the other study involving recreational athletes, GH enhanced sprint capacity, a 
performance measure dependent on the AES (8). The physiological significance of these findings is 
unclear.  
 
This thesis investigates GH regulation of the AES in adults with GHD and its significance. The 
literature review will provide an overview of the consequences of GHD and the effects of GH on 
body composition, substrate metabolism and muscle function and relate the information on function 
to muscle structure and bioenergetics. 
 
 
 
 
1.1! GH effects on body composition 
 
Body composition refers to the compartments of the body with differing chemical composition and 
functional properties. It describes the percentage of fat, muscle and bone in the body. GH plays a 
vital role in regulating body composition by stimulating lipolysis and protein synthesis. 
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Various techniques are used to estimate body composition. These include quantifying total body 
water by isotope dilution (9, 10), total body potassium by 40K counting (10-12), dual-energy x-ray 
absorptiometry (DXA) (13-17), computerized tomography (CT) (11, 18-21) and magnetic 
resonance imaging (MRI) (22, 23). These methods rely on various assumptions such as constant 
hydration state of lean body mass (LBM), constant intracellular potassium concentration or a 
constant fat-free extracellular compartment (3). These assumptions may not necessarily apply to 
adults with GHD and hence, caution must be exercised while interpreting results of body 
composition measurements. Although, each method relies on different principles, similar results are 
obtained. These studies have reported that adults with GHD manifest an increase in fat mass, more 
pronounced in abdominal and visceral adipose depots and a reduction in LBM compared to healthy 
controls (9, 10, 16, 24-26). Majority of these studies report that adults with GHD have 7-8% 
reduction in LBM, corresponding to around 4kg LBM (12, 27-30) and 7% increase` in fat mass (10, 
16, 24-27, 31). 
 
GH replacement therapy restores body composition to normal. On average up to a 5 kg increase in 
LBM and an equivalent reduction in fat mass occurs after replacement therapy without a change in 
body weight (3, 6, 12, 20, 26, 27, 31-39). Long-term studies of up to 10 years report that the 
beneficial effects of GH on body composition are sustained (11, 14, 40). Men are more responsive 
to GH replacement therapy than women. The cause is unclear but likely to involve the divergent 
modulatory effects of oestrogen and androgens on the action of GH (41). 
 
It is generally accepted that changes in LBM due to GH replacement reflect its effects on skeletal 
muscle. This has been demonstrated in studies showing a parallel increase in thigh cross-sectional 
area (28, 37). Most of the initial trials used higher doses of GH than currently recommended by 
guidelines (42). These higher doses were associated with fluid retention causing significant 
cardiovascular adverse effects (43, 44). A recent meta-analysis of placebo-controlled randomized 
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trials investigating GH effects on body composition found a dose-response relationship on LBM 
and fat mass (45).  It showed a 3.93 ± 1.5 kg increase in LBM and a 3.93 ± 1.05 kg decrease in fat 
mass for each mg increase in GH dose. 
 
In conclusion, body composition in adults with GHD is abnormal, as a consequence of a reduction 
in LBM and an increase in fat mass, changes that are reversed by GH replacement.  
 
1.2! GH effects on muscle mass and strength 
 
Muscle strength is defined as maximal force (in newtons, N) or torque (in newton-metres, N.m) that 
is generated by a muscle or a group of muscles during maximal voluntary contraction (46). This 
force is determined by fast twitch type II muscle fibres and relies on preformed ATP for energy 
(47). Muscle strength is commonly assessed by measuring the force or torque produced during 
isometric or isokinetic contraction. Isometric strength is the maximal voluntary contraction that can 
be developed against an immovable object without a change in joint angle, whilst isokinetic 
strength is a measure of torque/force through a range of motion in which limb is moving at a 
constant velocity (46). 
 
Muscle strength is significantly reduced in adults with GHD (48, 49) (Table 1.1). The force 
generated is usually corrected for muscle area (cm2) or volume (cm3) to distinguish between the 
contributions of muscle mass and contractile quality. Janssen et al. reported a significant reduction 
in strength and volume of quadriceps muscle in adults with GHD compared to those of age- and 
height-matched controls (50). These findings suggest that diminished strength in GHD arise from 
reduced muscle mass rather than from reduced contractile function. Sartorio et al. found that the 
strength of quadriceps muscle in adults with GHD was reduced in proportion to a reduction in 
muscle mass (32). These results stand in contrast to those of Cuneo et al. who found that quadriceps 
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muscle force was reduced in adults with GHD when corrected for muscle area (51). These authors 
hypothesized that contractile properties, energy metabolism or neuromuscular function of skeletal 
muscle are impaired in the GH deficient state. Janssen et al. attributed the disagreement to the 
possible inaccurate muscle mass assessment from a single slice CT scan (51) as opposed to a more 
precise method from using multiple MRI slices in their study (50). Muscle biopsy studies in adults 
with GHD have failed to identify any qualitative differences in fibre types compared to healthy 
adults. Thus, it is likely that muscle strength in GHD is reduced from diminished mass rather than a 
change in contractile quality. 
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Table 1.1 Studies comparing muscle strength of adults with GHD with healthy controls 
 
Study Total No. 
Mean Age 
years 
Gender 
(M:F) Type Diagnostic Criteria Control Outcome 
(48) 56 45±2 35:21 Mixed Peak GH <1.7µg/L during 
insulin induced 
hypoglycaemia 
Reference population of 
Goteborg. n=144, age 40-
79 years matched for mean 
Ht and Wt 
Lower isometric muscle strength in quadriceps and 
hamstring muscles. 
The peak handgrip strength was 83% and average 10-s 
handgrip strength was 81% of healthy control. 
 
(49) 14 41.8±17.3 9:5 Mixed Peak GH <6.0mU/L 
during insulin induced 
hypoglycaemia or oral 
clonidine 
14 age and gender 
matched controls. 
Lower isometric strength (84% of maximal predicted 
value for age gender and Ht). 
 
(50) 28 49±2 28:0 Mixed Peak GH <7.0mU/L 
during insulin induced 
hypoglycaemia 
20 age and Wt matched 
controls 
Lower maximal isometric strength. 
Maximal isokinetic strength tended to be lower (p=0.06) 
 
(51) 24 39±2 16:8 AO Peak GH <3.0mU/L 
during insulin induced 
hypoglycaemia 
41 age, gender and Wt 
matched controls 
Lower quadriceps force/body Wt (N/kg). Lower 
quadriceps force/quadriceps area (N/cm²). 
 
(32) 8 29.6±3.4  8:0 CO Peak GH < 5.0ng/ml to 
GHRH plus galanin & also 
to L-dopa plus propranolol 
 
8 age and gender matched 
controls 
Lower quadriceps isometric strength (63% of the 
controls) 
(52) 6 29±3  3:3 CO Peak GH < 3.4µg/L to 
insulin plus arginine 
stimulation test 
Published normal values Lower torque at speed of 30°/s and angular position of 
45° during knee flexion/extension 
Wt, weight; Ht, height; CO, childhood onset; AO, adult onset; N, Newton; GH, growth hormone; GHD, growth hormone deficiency; GHRH, growth hormone releasing hormone 
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Studies investigating the effects of GH replacement on muscle strength have provided conflicting 
results (Table 1.2 and 1.3). Jorgensen et al. observed that muscle strength did not change 
significantly after GH replacement for 4 months (20) but improved significantly after 12 months, 
with the improvement sustained at the end of 38 months of treatment (37, 53). 
 
 
Similarly, a number of other investigators have observed a lack of effect in the short term but a 
significant increase in muscle strength after extended treatment (34, 54-56). In an open label 
prospective study of 109 adults with GHD, GH therapy normalized the strength of different muscle 
groups over 10 years of therapy (57). The majority of studies assessing GH effects beyond 12 
months have reported a significant improvement in muscle strength (48-50, 57, 58), whereas trials 
of less than 6 months duration have not (20, 28, 34, 54-56, 59). The studies that show an increase in 
strength, also report a concomitant increase in muscle mass after long-term GH therapy (37, 50, 53). 
The collective findings indicate that GH replacement beyond 12 months is required to improve 
muscle strength in adults with GHD, reflecting the time taken to restore muscle mass towards 
normal. In summary, the collective evidence indicates that GH increases muscle strength by 
increasing muscle mass.  
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Table 1.2 The effects of GH on muscle strength in adults with GHD: Summary of Placebo-Controlled trials 
 
Study GHD patients Diagnosis of GHD Study Design  GH Dose Effects of GH compared to placebo 
 
(20) n=22 
M:F 14:8, CO 
Mean Age 23.8±1.2 
years 
Peak GH < 5µg/L after 
clonidine stimulation test 
4 months DBPC 
crossover 
2IU/m² No significant change in isometric strength 
(60) n=55 
M:F 31:24, AO 
Mean Age 49 years 
Peak GH < 3µg/L to 
insulin induced 
hypoglycaemia 
9 months DBPC 
crossover, 4 
months washout 
1.2IU/day for men 
1.8IU/day for women 
No significant change in isokinetic knee extensor strength 
(54) n=53 
M:F 23:20, mixed 
Age 21-60 years  
Peak GH < 5mg/L during 
insulin induced 
hypoglycaemia or 
GHRH stimulation test 
6 months DBPC  0.125IU/kg/week for first 
week; thereafter 
0.25IU/kg/week 
No significant change in strength  
 
(59) n=28 
M:F 15:13, AO 
Age 18-68 years  
Peak GH <3.0µg/L 
during insulin induced 
hypoglycaemia 
3 months DBPC 
crossover, 1 
month washout  
6.25µg/kg LBM for first 
month; 
12.5µg/kg LBM thereafter 
No significant change in isometric handgrip strength, isotonic 
arm, leg or chest press or isokinetic knee flexion / extension 
strength 
(34) n=40 
M:F 19:21, mixed 
Age 19-67 years  
Peak GH <6.0mU/L 
during insulin induced 
hypoglycaemia or oral 
clonidine 
6 months DBPC 0.02 to 0.05IU/kg   
 
No significant change in strength  
(56) n=30 
M:F 10:20, mixed 
Age ~35 years  
Peak GH <10.0mU/L 
after glucagon or insulin 
induced hypoglycaemia 
6 months DBPC  
 
0.125U/kg/week for first 
month; thereafter 
0.25U/kg/week 
No significant change in isometric quadriceps muscle strength 
(21) n=29 
M:F 19:10, AO 
Mean Age 45.5±2 
years  
Peak GH <10.0µg/L 
during insulin induced 
hypoglycaemia 
12 months 
DBPC 
2IU/m² No significant change in isometric quadriceps strength  
(61) n=24 
M:F 16:8, AO 
Mean Age 39±2 
years  
Peak GH <3.0mU/L 
during insulin induced 
hypoglycaemia 
6 months DBPC 0.07U/kg/day Significant increase in hip flexion strength 
(55) n=35 
M:F 18:17, mixed 
Mean Age 39.8 years  
Peak GH <10.0mU/L 
after glucagon or insulin 
induced hypoglycaemia 
6 months DBPC 0.125IU/kg/week for first 4 
weeks; thereafter 
0.25IU/kg/week 
No significant change in isometric quadriceps strength 
 
(28) n=14 
M:F 9:5, AO 
Peak GH <7.0mU/L 
during insulin induced 
6 months DBPC 
crossover with 1 
0.5U/kg/week No significant change isokinetic knee extension strength 
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Study GHD patients Diagnosis of GHD Study Design  GH Dose Effects of GH compared to placebo 
 
Mean Age 29.4±2.7 
years  
hypoglycaemia month washout 
(52) n=6 
M:F 3:3, CO 
Mean Age 29±3 
years   
Peak GH < 3.4µg/L 
during insulin plus 
arginine stimulation test 
3 months DBPC 
crossover with 3 
month washout 
0.5-0.6IU/kg/week No significant change in isokinetic knee flexion and extension 
strength 
DBPC, double blind placebo controlled; Wt, weight; Ht, height; CO, childhood onset; AO, adult onset; GH, growth hormone, GHD, growth hormone deficiency, IGFI, insulin like 
growth factor I; GHRH, growth hormone releasing hormone; LBM, lean body mass 
 
Table 1.3 The effects of GH on muscle strength in adults with GHD: Summary of open label trials 
 
Study GHD patients Diagnosis of GHD Study Design  GH Dose Effects of GH 
 
(53) n=13 
M:F 9:4, CO 
Mean Age 24.4±1.7 
years 
Peak GH < 5µg/L after 
clonidine stimulation test 
16 months open 
label 
Median 2.9IU/m² 
(1.2-3.8IU/m²) 
Significant increase in isometric strength of quadriceps  
(37) n=10 
M:F 7:3, CO 
Mean Age 28.4±2.3 
years 
Peak GH < 5µg/L after 
clonidine stimulation test 
37.6 months 
open label 
2IU/m² Significant increase in isometric strength of quadriceps 
(58) n=109 
M:F 61:48, AO 
Mean Age 50 years  
Peak GH < 3µg/L during 
insulin hypoglycaemia 
(n=95);  
2 additional hormone 
deficiency plus 24h GH 
profile (n=9); 1 
additional hormone 
deficiency plus 1 
stimulation test (n=4) 
5 years open 
label 
First 80 patients, starting 
dose 0.25IU/kg/week and 
individualized when Wt 
based regimen abandoned. 
In other patients, 
individualized from the 
beginning. 
Significant increase in isometric knee flexor strength, concentric 
knee flexor strength and right handgrip strength. 
No significant increase in isometric knee extensor strength, 
concentric knee extensor strength and left handgrip strength. 
(32) n=8 
M:F 8:0, CO 
Mean Age 29.6±3.4 
years 
Peak GH < 5ng/ml 
during 2 stimulation 
tests, GHRH plus galanin 
and L-dopa plus 
propranolol 
6 months open 
label 
0.5IU/kg/week Significant increase in isometric quadriceps strength. 
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Study GHD patients Diagnosis of GHD Study Design  GH Dose Effects of GH 
 
(54) n=53 
M:F 23:20, mixed 
Age 21-60 years  
Peak GH < 5mg/L during 
insulin induced 
hypoglycaemia or 
GHRH stimulation test 
6 months open 
label 
0.125IU/kg/week for first 
week; thereafter 
0.25IU/kg/week 
Significant increase in knee extension and arm flexion strength. 
(34) n=40 
M:F 19:21, mixed 
Age 19-67 years  
Peak GH <6.0mU/L 
during insulin induced 
hypoglycaemia or oral 
clonidine 
12 and 18 
months open 
label 
0.05IU/kg 
 
12 months: Significant increase neck flexion, elbow flexion and 
extension, and hip flexion and extension 
18 months: Significant increase in neck flexion and elbow 
extension  
(49) n=6 
M:F 3:3, mixed 
Mean Age 41.8±17.3 
years  
Peak GH <6.0mU/L 
during insulin induced 
hypoglycaemia or oral 
clonidine 
6 to 24 months 
open label  
0.04±0.01IU/kg/day Significant increase in maximal voluntary isometric strength. 
(56) n=30 
M:F 10:20, mixed 
Age ~35 years  
Peak GH <10.0mU/L 
after glucagon or insulin 
induced hypoglycaemia 
6 months open 
label 
2 years open 
label (n=12) 
0.125U/kg/week for first 
month; thereafter 
0.25U/kg/week 
6 months: No significant change in isometric quadriceps muscle 
strength. 
2 years: Significant improvement in quadriceps muscle strength  
(50) n=28 
M:F 28:0, mixed 
Mean Age 49±2 
years  
Peak GH <7.0mU/L 
during insulin induced 
hypoglycaemia 
12 months open 
label 
First 24 week, 0.6, 1.2 or 
1.8U and thereafter 
individualized dosing to 
normalize IGFI 
Significant increase in isokinetic muscle strength. 
No change in isometric muscle strength. 
(48) n=56 
M:F 35:21, mixed 
Mean Age 45±2 
years  
Peak GH <1.7µg/L 
during insulin induced 
hypoglycaemia 
2 years open 
label 
Individualized according to 
IGFI level. Mean GH dose 
0.62±0.03mg/day 
Significant increase in knee extension and flexion strength 
No change in handgrip strength. 
(55) n=35 
M:F 18:17, mixed 
Mean Age 39.8 years  
Peak GH <10.0mU/L 
after glucagon or insulin 
induced hypoglycaemia 
6 months open 
label 
0.125IU/kg/week for first 4 
weeks; thereafter 
0.25IU/kg/week 
Significant increase in isometric quadriceps muscle strength  
Wt, weight; Ht, height; CO, childhood onset; AO, adult onset; GH, growth hormone, GHD, growth hormone deficiency, IGFI, insulin like growth factor I; GHRH, growth hormone 
releasing hormone; LBM, lean body mass 
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Implicit in these studies of GH and muscle strength is the mediatory role of insulin like growth 
factor I (IGFI), which stimulates proliferation and differentiation of satellite cells into myoblasts 
and formation of new myofibres (62, 63). IGFI knockout mice exhibit muscle hypoplasia (64), 
whereas overexpression of IGFI leads to muscle hypertrophy (65) and accelerates muscle 
regeneration after disuse atrophy (66). Kim et al. observed a significantly increased muscle mass 
and stimulation of satellite cells and myofibre hypertrophy in skeletal muscle of wild type mice 
treated with GH, but these effects were absent in mice that lacked a functioning IGFI receptor in 
skeletal muscle (67). These studies indicate that the action of GH on muscle growth and strength are 
mediated via IGFI. 
 
Only a few double blind placebo controlled studies have investigated the effect of GH on muscle 
strength in healthy adults (8, 68-71). A 6-week GH administration failed to demonstrate any effect 
on maximal muscle strength in 8 healthy males (68). Similarly, in a study of nearly 100 recreational 
athletes, muscle strength did not increase after 8-week of GH treatment (8). GH administration in 
16 healthy men combined with resistance exercise did not further enhance muscle strength more 
than exercise alone after 3 months (69). Studies in healthy elderly subjects have also failed to 
observe any increase in muscle strength following 6 months of GH therapy (70, 71). These studies 
suggest that short-term GH therapy does not enhance muscle strength in healthy adults; however, 
the effects of long-term GH treatment are yet to be evaluated in this population. 
 
In summary, GH increases muscle strength by increasing muscle mass in adults with GHD, an 
effect that is IGFI mediated. At present, there is no evidence to support a role of GH in the 
enhancement of contractile function of skeletal muscle. 
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1.3! GH regulation of functional muscle proteins and muscle fibre type distribution 
 
Skeletal muscle is composed of fibres that are made up of different proteins with distinct properties. 
Actin and myosin are functional proteins that are responsible for the contractile function of muscle, 
whereas tropomyosin and troponin are structural proteins that keep the contractile proteins in proper 
alignment, and give muscle fibres elasticity and extensibility. Myosin protein consists of 2 heavy 
chains and 4 light chains. Muscle fibres are classified by myosin heavy chain (MHC) isoforms 
mainly into 2 types (72). Type I fibres, also known as slow twitch fibres, contain an abundance of 
mitochondria and rely on aerobic or oxidative pathways for energy production. These fibres 
determine the endurance capacity of muscle. In contrast, type II fibres, also known as fast twitch 
fibres, generate energy from anaerobic or glycolytic pathways due to their low mitochondrial 
content. These fibres have high contractile force, but easy fatigability. They subserve high intensity 
activities such as sprinting and weight lifting.  
 
MHC isoforms are distinguished by various methods including myofibrillar adenosine 
triphosphatase staining (73), immunohistochemistry with specific MHC isoform antibodies (74) and 
electrophoretic isoform separation (75). Several factors determine fibre type distribution in skeletal 
muscle. These include age, exercise, functional usage, neural input and hormones (76). For 
example, ageing is associated with a reduction in type II fibres (77), whereas thyroid hormone 
excess leads to a reduction in type I fibres (78). The effects of GH on contractile muscle proteins 
have been investigated in rodents and humans by studying the consequences of GHD and GH 
treatment.  
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1.3.1! Animal Studies 
 
Yamaguchi et al. reported a significant increase in type I fibres and decrease in type II fibres in 
rodents after hypophysectomy (79). These findings were supported by Roy et al., who observed a 
significant increase in fibres expressing MHC type I in hypophysectomized rats (80). A study 
investigating the long-term effects of hypophysectomy in rats reported a complete loss of type II 
fibres after 33 months (81). In contrast to these findings, Ayling et al. reported 50% reduction in 
type I fibres after hypophysectomy (82). Loughna et al. also observed a significant reduction of type 
I and an increase in type II MHC mRNA expression in hypophysectomized rats (83). In these 
studies, GH replacement almost completely reversed the changes observed after hypophysectomy 
(82, 83). However, some studies have reported no change in the composition of type I or type II 
fibres after GH replacement in hypophysectomized rats (80, 84). The reasons for these 
discrepancies are unclear. Possible explanations include the variable duration of GHD, which 
ranged between 21 days to 50 days, and the duration of GH therapy, which ranged from 7 days to 
33 months.  Most studies did not account for the effects of other pituitary hormone deficiencies on 
muscle fibre types, in particular thyroid hormone. When investigating the effects of GH in normal 
rats, Florini et al. observed no significant change in the number of type I or type II fibres after six 
months (85). These results in normal rats have been confirmed by other groups (86-88).  
 
1.3.2! Human Studies 
 
There are few human studies investigating GH regulation of muscle fibre composition, and most of 
these entail small numbers. Most studies in adult subjects with GHD have reported no significant 
difference in fibre type distribution from matched normal subjects (89-91). A time-dependent 
relationship between the duration of GHD and fibre type composition is unlikely from a comparison 
of findings between patients with childhood-onset and adult-onset GHD (89-91). Daugaard et al. 
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found no relationship between IGFI levels and MHC composition, suggesting that the severity of 
GHD does not influence MHC composition (92). Studies of GH replacement up to 6 months have 
reported no significant change in muscle fibre composition in adults with GHD (90-92). One of 
these studies reported an increase in muscle size and improvement in endurance capacity, but 
observed no change in the number of type I or II fibres (90). It is unclear from this study whether 
the relationship between the improvement in endurance and in type I fibre size is associative or 
causal. This study did not test muscle function reflective of type II fibre type that subserve high 
intensity contractile activity. There is insufficient evidence to support a role of GH in regulating 
type I or II fibres in human skeletal muscle, and more studies with larger numbers are required to 
determine whether GH regulates skeletal muscle fibre composition.  
 
1.4! GH effects on protein metabolism 
 
Protein turnover is defined as the continuing breakdown and synthesis of proteins, with recycling of 
amino acids. At a steady state, the rate of protein breakdown equals the rate of protein synthesis, 
and there is no net gain or loss of proteins. Amino acids released from protein breakdown are either 
reutilized in protein synthesis or irreversibly lost via oxidation. Over the last 2 decades, isotope 
tracer methods such as leucine turnover technique have made it possible to accurately measure 
these components of whole body protein metabolism by tracking the metabolic fate of a labeled 
amino acid (93).  
 
LBM and muscle mass are reduced in adults with GHD suggesting that there is an underlying 
perturbation of protein metabolism (6). Hoffman et al. compared protein metabolism in 10 patients 
with GHD and healthy controls using labeled leucine and found that the rate of protein synthesis 
and breakdown were significantly reduced in GHD subjects (94). These results corroborate previous 
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findings of Beshyah et al. and suggest that the whole body protein turnover is reduced in adults with 
GHD (95). 
 
GH replacement in adults with GHD improves protein balance by partitioning amino acids away 
from oxidative towards synthetic pathways (96-100). Russell-Jones et al. observed an increase in 
protein synthesis and a reduction in protein oxidation without any change in protein breakdown 
after 2 months of GH in subjects with GHD (99). The same findings were obtained by Shi et al. 
following 2 weeks, and by Binnerts et al. after 1 month of GH therapy in adults with GHD (27, 
100). These anabolic effects of GH are also observed in healthy adults supplemented with GH. In 
healthy subjects, Copeland and Nair et al. observed an acute reduction in whole body protein 
oxidation following GH administration (101). Similar effects were reported by Horber and 
Haymond et al. in a study undertaken in a fasting and fed state following 7 days of GH treatment in 
healthy volunteers (102). 
 
Long-term studies in adults with GHD have observed attenuation in anabolic effects after prolonged 
therapy (95, 100). Binnerts et al. observed that GH-induced reduction in protein oxidation was 
diminished after 6 months of GH therapy (27). In another study, the reduction of protein oxidation 
seen at 2 weeks of GH therapy had returned to baseline at 12 weeks, indicating a waning GH effect 
with time (103). Studies have shown that the reduction in protein oxidation is a predictor of a later 
increase in LBM, which occurs over the first few months (95, 103). Thus, GH causes a time-
dependent change in whole body protein metabolism. In the early weeks, GH reduces the rate of 
protein oxidation, leading to an accrual of protein mass. However, as the increase in LBM begins to 
plateau, there is a gradual return in the rate of protein oxidation to baseline, protein balance reaches 
a new steady state. The metabolic mechanisms accounting for this adaptation are unknown. 
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Whole body protein turnover studies do not provide information regarding the site of protein 
synthesis although it is widely assumed that this is muscle. To address the direct effects of GH on 
skeletal muscle protein turnover, investigators have measured the arterio-venous difference of 
labeled and unlabeled amino acids across the forearm or leg (93). Using this technique, Fryburg et 
al. reported that GH induced an increase in protein synthesis without affecting the rate of protein 
breakdown in forearm muscles (104, 105). However, Copeland et al. found no significant 
stimulation of protein synthesis in the leg during GH infusion, despite observing a concomitant 
stimulation of whole body protein synthesis (101). The latter findings were corroborated by 
Yarasheski et al. who also failed to observe any effect on protein synthesis of quadriceps muscle 
following GH therapy (106). These observations suggest a greater proportion of whole body protein 
anabolism occurs in tissues and organs than in skeletal muscle. This could explain why the 
improvement by GH in muscle strength in GHD is slow, and the paucity of evidence supporting a 
beneficial effect in GH replete subjects. 
 
According to the somatomedin hypothesis, the anabolic action of GH is mediated by circulating 
IGFI, which is mainly derived from the liver (107, 108). However, it is recognized that IGFI, 
produced locally in tissues under GH stimulation, mediate some of the growth promoting actions of 
GH. (62, 108). The extent to which circulating and local IGFI contributes to tissue growth has been 
the subject of great interest in the field and remains controversial.  Human studies employing 
recombinant IGFI provide the strongest evidence that circulating IGFI is anabolic. IGFI enhances 
protein anabolism by reducing the rate of proteolysis, an action similar to that of insulin (109-111). 
When IGFI is infused in rats, it leads to a reduction in protein breakdown without any change in 
protein synthesis (110). Thus, the protein anabolic effects of systemic IGFI are similar to insulin 
and different from GH, which regulates the metabolic fate of amino acids from oxidative to 
synthesis pathways. These observations indicate that the effects of GH on amino acid fluxes are 
mediated by mechanisms in addition to those mediated by IGFI.  
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In summary, GH regulates protein anabolism via IGFI-dependent endocrine and paracrine 
mechanisms as well as IGFI independent pathways. The net effect of GH on whole body protein 
metabolism is the metabolic partitioning of amino acids towards synthesis and away from 
irreversible oxidative loss, but with tissue effects that differ between muscle and extra-muscular 
tissues. 
 
1.5! GH and substrate metabolism in skeletal muscle 
 
1.5.1! Bioenergetics in skeletal muscle 
 
1.5.1.1! The Energy Continuum 
 
The contractile function of skeletal muscle relies on a constant supply of chemical energy. During 
muscle contraction, chemical energy is converted to mechanical energy that leads to movement. In 
humans, chemical energy is available in the form of ATP, which is generated by two energy 
systems: aerobic and anaerobic (4). The aerobic energy system relies on oxygen whereas the AES 
does not. Although, both systems function as a continuum, physical activity/exercise is described in 
terms of aerobic or anaerobic, depending on which system predominates. Figure 1.1 illustrates the 
metabolic processes involved in energy production in a muscle cell and the concept of energy 
continuum during physical activity. 
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Figure 1.1 Anaerobic and aerobic energy systems.  
AA, amino acid; FA, fatty acid; TCA, tricarboxylic acid cycle 
 
 
 
 
1.5.1.1.1! Glycolysis  
 
Glycolysis, or glucose breakdown, is an essential pathway of energy metabolism in all tissues. 
Glycolysis leads to the formation of either pyruvate or lactate depending on the oxidative status of 
the cell (Figure 1.1). Pyruvate is the end product of glycolysis in cells with mitochondria and 
adequate oxygen supply. This series of reactions is called aerobic glycolysis because oxygen is 
required to reoxidize NADH (reduced nicotinamide adenine dinucleotide), an energy-rich 
coenzyme formed during the process. Pyruvate is then converted into Acetyl CoA by an enzyme 
located in mitochondrial matrix called pyruvate dehydrogenase (PDH). Acetyl CoA is a major 
source of fuel for oxidative energy production in mitochondria. In tissues with inadequate oxygen 
supply (for example, skeletal muscle during intense exercise) or cells that lack mitochondria (for 
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example, red blood cells), pyruvate is reduced by NADH in the presence of lactate dehydrogenase 
(LDH) to form lactate. This conversion of glucose to lactate is called anaerobic glycolysis because 
there is no net gain of NADH. Lactate is then released into the blood and converted back to glucose 
via gluconeogenesis in the liver. 
 
Aerobic or anaerobic glycolysis to pyruvate or lactate yields 2 ATP. The subsequent metabolism of 
the 2 pyruvate molecules yields 34 ATP on complete oxidation via the tricarboxylic acid (TCA) 
cycle and oxidative phosphorylation in the mitochondrial respiratory chain. 
 
Stoichiometry of glucose metabolism 
 
Anaerobic glycolysis: 
Glucose + 2 Pi + 2 ADP                   2 Lactate + 2 ATP + 2 H2O 
 
Aerobic glycolysis: 
Glucose + 2 Pi + 2 NAD+ + 2 ADP   2 Pyruvate + 2 ATP + 2 NADH + 2 H+ + H2O 
 
Complete oxidation of glucose: 
Glucose + 6 O2 + 36 Pi + 36 ADP    36 ATP + 6 CO2 + 42 H2O  
 
1.5.1.1.2! The aerobic energy system 
 
The aerobic energy system relies on the generation of ATP from oxidation of Acetyl CoA in the 
mitochondria. Acetyl CoA is derived from the metabolism of substrates such as carbohydrates, 
lipids and protein. It undergoes a series of reactions in the TCA cycle where four pairs of electrons 
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via energy-rich coenzymes are transported to the mitochondrial respiratory chain, generating 12 
ATP from each molecule of Acetyl CoA oxidized. 
 
The aerobic energy system provides energy at rest, as well as that required for sustaining long 
duration of physical activity such as prolonged walking at a comfortable pace. During the transition 
from rest to physical activity, oxygen consumption is increased to meet the increased energy 
demands. After a few minutes, the rate of oxygen consumption reaches a new steady state and 
oxidative energy production matches energy consumption. However, the body relies predominantly 
on anaerobic energy at the start of any physical activity, until aerobic energy metabolism increases 
to supply the new energy needs. 
 
1.5.1.1.3! The anaerobic energy system 
 
The AES is comprised of an alactic system and a lactic acid system (5). The alactic system (Figure 
1.2) consists of preformed ATP and phosphocreatine (PCr), which donates a phosphate group to 
ADP (adenosine diphosphate) to form ATP instantaneously. The lactic acid system provides energy 
from anaerobic glycolysis. The alactic system provides energy for the first few seconds (~ 10 
seconds) of physical activity; thereafter anaerobic glycolysis provides energy for the next 30-40 
seconds, when aerobic metabolism begins to take over and provides energy for prolonged sustained 
activity (112). 
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Figure 1.2 Alactic anaerobic system.  
ADP, adenosine diphosphate; ATP, adenosine triphosphate 
 
 
 
 
 
1.5.2! GH effects on substrate metabolism in skeletal muscle 
 
Muscle function is dependent on the availability of metabolic fuels and its capacity to synthesize 
ATP. The energy synthesis from substrate utilization in exercising muscle is regulated by 
nutritional, genetic, and hormonal factors as well as physical training.  GH stimulates lipolysis at 
rest (113-115) and during exercise (116, 117), leading to an increase in plasma fatty acid (FA) 
levels. GH also increases plasma glucose concentration by various mechanisms including 
augmentation of glycogenolysis (118) and gluconeogenesis (119). Thus, GH may enhance muscle 
function by increasing availability of FA and glucose as metabolic fuels for energy production.  
 
GH stimulates whole body lipid oxidation and reduces carbohydrate utilization in healthy adults 
(113, 120, 121) and in adults with GHD (122-124). Given that LBM accounts for the majority of 
substrate metabolism in the body (125), and muscle comprises almost 50% of total LBM, it is 
widely assumed that an increase in whole body lipid oxidation is a reflection of its action on 
skeletal muscle, however, very limited evidence is available to support this assumption. This 
traditional thinking was recently challenged by studies in rodents as well as humans, indicating that 
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GH action is rather tissue specific. These studies used DNA microarray technology as a platform to 
study GH effects on global changes in metabolic gene expression in the target tissues. 
 
 
Tollet-Egnell et al. studied effects of GH on liver and skeletal muscle of rats (126). In the liver, GH 
reduced expression of genes for lipid synthesis, such as fatty acid synthase and stearyl-CoA 
desaturase, but increased genes for fat oxidation including carnitine palmitoyl transferase I (CPT I), 
a key enzyme for the transfer of FA from cytosol into the mitochondrial matrix. Whereas in skeletal 
muscle, genes for FA uptake were reduced, and glycolysis were increased upon GH treatment. 
These data indicate that GH action on substrate metabolism is tissue specific.  
 
 
Sjogren et al. studied effects of GH replacement on metabolic gene expression in skeletal muscle of 
adults with GHD (7). These authors found a striking difference between the whole body and 
skeletal muscle substrate metabolism following GH treatment. GH stimulated whole body resting 
energy expenditure, lipid oxidation and reduced carbohydrate oxidation. In skeletal muscle, 
however, GH downregulated key genes governing lipid oxidation, TCA cycle activity and 
mitochondrial respiration as well as genes that suppress glucose utilization (Figure 1.3). Expression 
of genes involved in FA transport such as fatty acid binding protein-3 (FABP-3) and CTP-I fell by 
50%. Genes for several enzymes that mediate β-oxidation of FA and ATP synthesis via oxidative 
pathway in the mitochondria were also suppressed in skeletal muscle following GH therapy. For 
example, the expression of oxoglutarate dehydrogenase and succinate dehydrogenase complex B in 
the TCA cycle and ATP synthase and NADH dehydrogenase in the mitochondrial respiratory chain 
were reduced by up to 40%. GH also reduced the transcripts levels of pyruvate dehydrogenase 
kinase-4 (PDK-4) and glycogen synthase-I in muscle. The latter has been shown in previous studies 
in healthy (127) as well as adults with GHD (128). PDK-4 is an inhibitor PDH, the key enzyme that 
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converts pyruvate to Acetyl CoA for oxidation in mitochondria (129). These findings indicate that 
GH favours glucose as a metabolic fuel over lipid in skeletal muscle. 
 
 
Figure 1.3 GH effects on metabolic gene expression in skeletal muscle.  
Schematic diagram of changes in the expression of key genes in skeletal muscle governing the 
oxidative metabolism of fatty acids and glucose after GH therapy [adapted from the study by 
Sjogren et al. (7)]. Metabolic genes that were down regulated by GH in skeletal muscle are boxed in 
green with the abbreviated names are expanded below. FA, Fatty acid; TCA, tricarboxylic acid 
cycle; ADP, adenosine diphosphate; ATP, adenosine triphosphate. Lipid metabolism: FABP3, Fatty 
acid-binding protein-3; ACSL, Acyl-CoA synthetase, long chain; CPTI, 
Carnitinepalmitoyltransferase I; ACAD8, Acyl-CoA dehydrogenase, family member 8; HADHA, 
Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase; TCA cycle: OGHD, Oxoglutarate 
dehydrogenase; SDHB, Succinate dehydrogenase complex B; Mitochondrial chain: OXA, Oxidase; 
NDU, NADH dehydrogenase; ATPS, ATP synthase 
 
 
 
Assuming that the transcriptional changes reflect effects on protein expression, these findings 
suggest that GH inhibits oxidative metabolism of substrates and may favour non-oxidative 
(anaerobic) pathways for ATP synthesis in skeletal muscle. This was a small uncontrolled study 
conducted in only 5 subjects with GHD administered GH for two weeks. However the findings are 
supported by a study in trained cyclists, in whom GH administration increased plasma lactate levels 
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during intense exercise compared to placebo, consistent with an increased rate of anaerobic disposal 
of pyruvate (130).  
 
In summary, the effects of GH on substrate metabolism are tissue specific. GH may promote non-
oxidative or anaerobic substrate metabolism in skeletal muscle for ATP synthesis, findings contrary 
to its effects on whole body metabolism. Further work is required to confirm gene expression 
findings in a larger cohort in a placebo-controlled design. 
 
1.6! GH effects on muscle power 
 
Muscle power is defined as work performed per unit of time and is expressed in joules per second 
or watts. It is described in terms of aerobic and anaerobic power, depending on which energy source 
is predominantly utilized to do the work. Thus, muscle power can be assessed by measuring aerobic 
exercise capacity and anaerobic exercise capacity.  
 
1.6.1! Aerobic exercise capacity 
 
Aerobic exercise capacity is a measure of endurance i.e. the muscle’s ability to sustain work for a 
prolonged period with energy provided principally from oxidation of carbohydrates or lipids in the 
mitochondria. In the athletic world, it determines performance in sports such as distance running 
and swimming, while in day-to-day life, it supports activities such as walking. Aerobic exercise 
capacity is a stronger predictor of mortality in men than any other established risk factors for 
cardiovascular disease such as hypertension, smoking, and diabetes (131). It is determined by the 
measurement of maximal oxygen uptake (VO2max) in L/min or ml/kg/min or maximal aerobic 
power output in watts or kilojoules during an incremental exercise test on a cycle ergometer or a 
treadmill (132). 
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Studies in subjects with GHD have provided strong evidence that GH is a significant positive 
regulator of aerobic exercise capacity. Cuneo et al. reported a mean reduction of 28% in VO2max in 
adults with GHD compared to their maximum predicted value based on age, weight and height 
(133). Many studies have reported a similar degree of impairment in aerobic exercise capacity in 
these individuals (28, 134, 135).  
 
Numerous double blind placebo controlled trials have investigated GH effects on aerobic exercise 
capacity in adults with GHD (Table 1.4). In a study of 22 adults with GHD, aerobic exercise 
capacity increased significantly after 4 months of GH therapy and was sustained for up to 38 
months of GH treatment (20, 37). Cuneo et al. observed a near normalization of VO2max over a 
period of 6 months with GH replacement in a study involving 24 adults with GHD (133). Most of 
these studies show an improvement in VO2max and/or maximal aerobic power output following GH 
therapy for 4 to 12 months (20, 21, 28, 37, 53, 60, 133, 134). A few studies failed to show a positive 
effect of GH on aerobic exercise capacity in comparison to placebo (43, 52, 59). This is likely due 
to a type II statistical error arising from the small number of participants in these trials. 
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Table 1.4 The effects of GH on aerobic exercise capacity in adults with GHD: Summary of Placebo-Controlled trials 
 
Study GHD 
Patients 
Age Diagnosis of GHD Study Design  GH Dose Method Effects of GH compared to placebo 
(20) n=22, CO 
M:F 14:8 
23.8±1.2 
years 
Peak GH < 5µg/L 
after clonidine 
stimulation test 
4 months DBPC 
crossover 
2IU/m² Cycle 
Ergometer 
Increase in exercise capacity  
(133) n=24, AO 
M:F 16:8 
39±2 
years 
Peak GH <3.0mU/L 
during insulin 
induced 
hypoglycaemia 
6 months DBPC 0.07U/kg/day Cycle 
Ergometer 
Increase in VO2max and maximal power output  
(21) n=29, AO 
M:F 19:10 
45.5±2 
years 
Peak GH <10.0µg/L 
during insulin 
induced 
hypoglycaemia 
12 months 
DBPC 
2IU/m² Cycle 
Ergometer 
Increase in exercise capacity  
(135) n=20, AO 
M:F 15:5 
~45 
years 
Peak GH < 2ng/ml 
during insulin 
induced 
hypoglycaemia  
6 months DBPC 12.5µg/kg/day Cycle 
Ergometer 
No change in VO2max 
Increase in maximal power output 
(43) n=10, AO 
M:F 9:1 
47 years Peak GH <5.0mU/L 
during insulin 
induced 
hypoglycaemia 
6 months DBPC 
crossover 
0.5U/kg/week Cycle 
Ergometer 
No change in maximal power output  
(28) n=14, AO 
M:F 9:5 
29.4±2.7 
years 
Peak GH <7.0mU/L 
during insulin 
induced 
hypoglycaemia 
6 months DBPC 
crossover with 1 
month washout 
0.5U/kg/week Cycle 
Ergometer 
Increase in exercise capacity and VO2max 
(55) n=35, mixed 
M:F 18:17 
39.8 
years 
Peak GH 
<10.0mU/L after 
glucagon or insulin 
induced 
hypoglycaemia 
6 months DBPC 0.125IU/kg/week 
for first 4 weeks; 
thereafter 
0.25IU/kg/week 
Treadmill No change in VO2max 
 
(60) n=55, AO 
M:F 31:24 
49 years Peak GH < 3µg/L to 
insulin 
hypoglycaemia 
(<2.2mmol/L) 
9 months DBPC 
crossover, 4 
months washout 
1.2IU/day for 
men 
1.8IU/day for 
women 
Treadmill Increase in VO2max 
(59) n=28, AO 
M:F 15:13 
18-68 
years 
Peak GH <3.0µg/L 
during insulin 
3 months DBPC 
crossover, 1 
6.25µg/kg LBM 
for first month; 
Treadmill No change in VO2max 
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Study GHD 
Patients 
Age Diagnosis of GHD Study Design  GH Dose Method Effects of GH compared to placebo 
induced 
hypoglycaemia 
month washout  12.5µg/kg LBM 
thereafter 
 
 
(34) n=40, mixed 
M:F 19:21 
19-67 
years 
Peak GH <6.0mU/L 
during insulin 
induced 
hypoglycaemia or 
oral clonidine 
6 months DBPC 0.02 to 
0.05IU/kg   
 
Treadmill No change in exercise capacity 
 
DBPC, double blind placebo controlled; VO2max, maximal oxygen uptake; CO, childhood onset; AO, adult onset; GH, growth hormone, GHD, growth hormone deficiency; LBM, lean body mass; W, watts; kJ, kilojoules 
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The underlying mechanisms responsible for the improvement in aerobic performance during GH 
replacement are multifactorial. Oxygen delivery to exercising muscles depends on cardiac function, 
lung capacity and oxygen carrying capacity of the blood (136). Adults with GHD have impaired 
cardiac function (137), diminished lung capacity (138) and reduced red cell mass (139). These 
deficits are restored with GH replacement. In adults with GHD, GH replacement increases i) 
cardiac output, which arises from enhancement of heart rate and stroke volume (20, 133, 135, 140); 
ii) lung capacity by increasing respiratory muscle strength and lung volumes (135, 138); and iii) red 
cell mass, which determines oxygen carrying capacity of the blood (139, 141, 142). As discussed 
previously, biopsy data in humans do not provide evidence that GH increases the number of 
oxidative type I muscle fibres. However, studies uniformly show that the increase in muscle mass is 
associated with an increase in oxygen consumption during GH replacement (28, 135).  These 
observations are consistent with the delivery of a greater amount of oxygen to an increased muscle 
mass as a result of GH replacement in adults with GHD, leading to an increase in aerobic capacity 
of exercising muscles. 
 
Several studies have failed to show any significant effects of GH on VO2max in healthy adults 
(143). Berggren et al. observed no significant increase in VO2max following 28 days of low dose 
(0.033 mg/kg/day) and high dose (0.067 mg/kg/day) GH in a double blind placebo controlled trial 
of 30 healthy adults (144). These findings were supported by the lack of improvement in VO2max 
of 96 recreational athletes following 8 weeks of GH administration (2mg/kg/day) (8). Thus, GH 
does not enhance aerobic exercise capacity in healthy adults. 
 
Collectively, these results indicate that GH enhances aerobic exercise capacity in subjects with 
GHD, but not in healthy adults. The improvement can be explained by effects on muscle mass, 
cardiorespiratory function and haematological parameters. 
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1.6.2! Anaerobic exercise capacity 
 
Anaerobic exercise capacity is defined as the total amount of work during a maximal exhausting 
exercise of a short duration, which is underpinned by anaerobic ATP supply (145). This work is 
executed by fast twitch type II muscle fibres. Various exercise tests have been used to assess 
anaerobic exercise capacity (146). In sporting activities that involve short-term high intensity 
physical activity, such as sprinting, baseball, gymnastics etc., the main energy source is anaerobic 
ATP. All physical activities including activities of daily living also depend on anaerobic energy 
upon initiation, for the first few seconds, before aerobic metabolism becomes the predominant 
energy source (5, 147). Thus, it is conceivable that a suboptimal AES impairs muscle function 
leading to easy fatigue in patients and diminished performance in athletes.  
 
Factors other than physical training that regulate anaerobic exercise capacity are largely unknown 
(5). So far only one study has investigated the effects of GH on anaerobic exercise capacity (8). 
This double blind placebo controlled study in a large group of recreational athletes reported a 
significant improvement in anaerobic exercise capacity after GH therapy for 8 weeks, as assessed 
by the Wingate test. GH did not increase body cell mass, the functional compartment of LBM that 
is predominantly composed of muscle, nor standard measures of muscle strength (dynamometry) 
and power (jump height) (Figure 1.4). These findings suggest that muscle anabolism is unlikely to 
explain the improvement in the Wingate test. Jump height represents instantaneous work whereas 
the Wingate test involves all-out intensive exercise on a cycle ergometer for 30 seconds. Although 
both tests measure anaerobic power, the energy required for jumping is drawn from PCr stores 
while that for the longer Wingate test, from PCr stores and that derived from glycolysis.  A likely 
explanation is a GH effect on energy supply stimulating ATP production from glycolysis, leading to 
an increase in anaerobic exercise capacity in skeletal muscle. As the effects were assessed in GH-
 49 
replete individuals treated with a supraphysiological dose of GH, the physiological and functional 
relevance of these findings remain unknown. 
 
 
Figure 1.4 GH effects on physical performance in recreational athletes.  
[Adapted from Meinhardt et al. (8)]. This figure illustrates the percent change after 
GH or placebo treatments in four measures of physical performance: VO2max, 
strength (dynamometry), jump height and Wingate test. 
 
 
 
 
In summary, the AES provides energy for initiation of all biological activities including activities of 
daily living and powers short-term high intensity physical activity (5, 147). Hence, the finding that 
GH may regulate the AES has potential therapeutic implications not only in the GH deficient 
population but also possibly in accelerating physical rehabilitation and improving physical function 
in the frail elderly. It also provides further justification of GH prohibition in sports. 
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1.7! GH effects on quality of life 
 
Many investigators have assessed QoL in adults with GHD. There is good evidence to suggest that 
GHD leads to impaired QoL (148-150).(151) Amongst the various domains of QoL, energy and 
vitality are the most affected areas in adults with GHD with easy fatigue a prominent symptom 
(152, 153).  
 
The question as to whether GH replacement improves QoL in adults with GHD has been 
investigated in many double-blind placebo-controlled and open label trials. Table 1.5 summarizes 
the findings of placebo-controlled trials investigating the effects of GH replacement on QoL in 
adults with GHD. The majority of these trials report a significant improvement (56, 149, 154-161). 
In a double-blind placebo-controlled trial involving 21 patients with GHD, a significant 
improvement in QoL occurred following 9 months of GH replacement; the domains that showed the 
great improvement were energy, emotions and cognitive function (148). The spouses who were also 
blinded to the intervention, observed a marked improvement in energy, mood and behavior in the 
subjects during GH therapy. Improvement of QoL is observed within first few months of starting 
the GH therapy. Some studies have reported an improvement as early as 3 months (151, 153, 162) 
although most occurs within the first year of GH replacement (6, 42). These benefits are sustained 
several years after starting the GH therapy (163, 164) and lost as early as 3 months after the 
withdrawal of GH replacement (157). The response to GH therapy is proportional to the baseline 
QoL deficit in patients with GHD (153, 165). This means that patients with a low QoL at the outset 
are likely to benefit most from GH replacement. 
 
The mechanisms that lead to impairment of QoL and restoration after GH replacement are unclear. 
Although, it seems reasonable to assume anabolic effects of GH on body composition, muscle 
strength and aerobic exercise capacity may play a role in restoration of QoL in adults with GHD, no 
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relationship has been found between QoL and these parameters (6, 165, 166). It is not known 
whether improvement in these anabolic performance measures lead to an improvement in physical 
function, which is likely to have a significant bearing on their QoL. Many studies have failed to 
detect a relationship between QoL and serum IGFI levels (164, 167). Also, aerobic exercise 
capacity and muscle strength improve only after long-term therapy (> 12 months), in contrast to 
improvement in QoL, which is seen within a few months, raising a possibility of GH effects other 
than muscle anabolism affects QoL in adults with GHD such as energy metabolism. Short term GH 
therapy improves anaerobic exercise capacity in healthy adults (8). If a similar effect occurs in GH 
deficient population, the stimulation of the AES could explain the early improvement in QoL of 
adults with GHD by increasing the availability of energy and reducing fatigue. 
 
In summary, adults with GHD experience impaired QoL, which improves within first few months 
after initiation of GH replacement and sustained long-term with continuation of GH therapy. 
Despite extensive research in this field, the mechanisms of QoL impairment in GHD and its 
restoration with GH replacement are not well understood.  
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Table 1.5 The effects of GH on quality of life in adults with GHD: Summary of Placebo-Controlled trials 
 
 
Study GHD patients Study 
Design 
GH dose QoL measure Effects of GH 
(149) N=24 
Age 18-55 
years 
6-month 
DBPC 
0.07 U/kg NHP 
 
PGWB 
GHQ 
Improvement in overall score compared to baseline and in energy compared to 
placebo 
Improvement in only mood subsection compared to baseline 
Improvement in overall scores compared to baseline 
(148) N= 36 
M:F 27:36 
Age 34.9 years 
21-month 
cross-over 
DBPC 
0.25IU/kg/week NHP 
HSCL 
 
PGWB 
Improvement in overall score compared to baseline 
Total score improved in both, placebo and GH groups. Cognitive impairment 
improved significantly in GH group compared to placebo. 
Improvement in overall score compared to baseline 
(154) N=40 males 18-month 
DBPC 
4 ± 2 mcg/kg NHP 
PGWD 
GHQ 
MMPI-2 
No difference 
No difference 
No difference 
No difference, On the Hysteria scale, a small increase in report of adverse 
symptoms in the GH group when compared with the placebo group  
(156) N=26 
M:F 12:14 
Age 51 years 
6-month 
DBPC 
3.7mcg/kg KSQ 
HDS 
No difference 
Improvement in GH group compared to baseline 
(15) N=166 
M:F 86:80 
12-month 
DBPC 
0.0125mg/kg BDI 
NHP 
PGWB 
PQ 
NHIS 
TMT 
No difference  
No difference 
No difference 
No difference 
No difference 
No difference 
(56) N=30 
M:F 10:20 
6-month 
DBPC 
0.25U/kg/week NHP 
 
HAS 
Self-esteem 
MFQ 
Impact scale 
Life fulfilment 
Improvement in Energy score in GH group compared to baseline 
 
No difference 
Improvement in placebo group  
No difference 
Improvement in GH group compared to baseline 
No difference  
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Study GHD patients Study 
Design 
GH dose QoL measure Effects of GH 
      
(168) N=50 males 6-month 
DBPC 
1.7 ± 0.8 IU/m2 HSCL 
POMS 
STAI 
No difference 
No difference 
No difference 
(160) N=9 
M:F 6:3 
6-month 
DBPC 
0.25 IU/kg/week HDS 
BDI 
Improvement in GH group compared to placebo 
Improvement in GH group compared to placebo 
(169) N=19 
M:F 13:6 
12-month 
DBPC 
3.6 IU/day GHQ No difference 
(158) N=165 
M:F 99:66 
6-month 
DBPC 
0.25 IU/kg/week NHP 
 
QoL-AGHDA 
Improvement in energy and emotional reaction in both groups and in social 
isolation in placebo group 
Improvement in GH group compared to baseline 
(155) N=38 
M:F 21:17 
6-month 
DBPC 
0.025mg/kg and 
0.012mg/kg 
NHP 
PGWB 
Improvement in GH group compared to baseline 
Improvement in both groups 
(170) N=166 
M:F 91:72 
6-month 
DBPC 
0.25 IU/kg/week NHP 
GHDQ 
No difference 
No difference 
(161) N=203 
M:F 100:103 
6-month 
DBPC 
0.07 IU/kg NHP 
PGWB 
GHQ 
Improvement in GH group compared to placebo 
Improvement in mood only in GH group compared to baseline 
Improvement in psychological distress in GH group compared to baseline 
(60) N=55 
M:F 31:24 
9-month 
DBPC 
1.8 IU in females, 
1.2 IU in males 
HSCL-58 
SF-36 
No difference 
No difference 
(157) N=21 
M:F 10:11 
3-month 
DBPC 
0.125-0.25 
IU/kg/week 
HDQoL 
GWBI 
W-BQ12 
SF-36 
NHP 
GHQ 
Deterioration in physical activity in placebo group 
No difference 
Deterioration in energy in placebo group 
Deterioration in general health in placebo group 
No difference 
No difference 
DBPC, double-blind placebo-controlled; QoL, quality of life; HSCL-58, Hopkins symptom checklist 58; SF-36, short form 36; AGHDA, adult GH deficiency assessment; NHP, 
Nottingham health profile; PGWB, psychological general well-being index; GHQ, general health questionnaire; MMPI-2, Minnesota Multiphasic Personality Inventory-2; POMS, 
profile of mood scales; STAI, state trait anxiety inventory; KSQ, Kellner symptom questionnaire; HDS, Hamilton depression scale; BDI, Beck depression inventory; HAS, hospital 
anxiety and depression scale; SE, self esteem scale; MFQ, mental fatigue questionnaire; PQ, Paffenbarger Questionnaire; NHIS, National Health Interview Survey; TMT, Trail 
Making Tests; HDQoL, Hormone Deficiency-Dependent quality of life questionnaire; GWBI, general well-being questionnaire; W-BQ 12, the well-being questionnaire  
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1.8! Statement of aims 
 
This chapter provides an overview of the consequences of GHD in adults and the effects of GH 
replacement in ameliorating these changes via its metabolic and anabolic properties. GHD leads to 
detrimental changes in body composition causing diminished muscle strength and endurance 
capacity (6). Strength and endurance are measures of muscle function that depend on muscle size, 
muscle fibre composition and the availability of energy to support the exercising muscle. This 
energy is available as ATP which is produced by two complementary energy systems: anaerobic 
and aerobic (4).  
 
The aerobic energy system supports endurance exercise whereas the AES powers intensive activity 
of short-term duration. The AES underpins the initiation of all physical activities including 
activities of daily living (5). Thus it is conceivable that impairment of anaerobic capacity increases 
fatigue, impairing the activities of daily living, a symptom commonly observed in adults with GHD 
(152).  
 
Muscle strength and aerobic capacity are impaired in GHD and restored by GH replacement over a 
period of few months (3, 6). Whether anaerobic capacity is impaired in GHD and improved with 
GH replacement has not been studied. A recent study reported that GH improves anaerobic capacity 
in healthy adults within few weeks of treatment, indicating an effect mediated via energy 
metabolism, rather anabolism (8). Sjogren et al. reported that GH suppressed genes in skeletal 
muscle governing lipid oxidation and stimulated genes promoting glycolysis in skeletal muscle. 
Although this gene expression study provides evidence supporting a role of GH in stimulating the 
AES, the results were derived from a small uncontrolled study (7, 8). The relationship between 
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anaerobic capacity, physical function and health-related QoL in adults with GHD, and the impact of 
GH replacement have not been investigated. 
 
The major aims of this thesis are to investigate whether:  
1.! anaerobic capacity is impaired in adults with GHD and is improved with GH replacement  
2.! there is a relationship between anaerobic capacity, and physical function and QoL 
3.! GH alters the expression profiles of skeletal muscle genes in favour of anaerobic 
metabolism  
 
The hypotheses to be tested are: 
1.! Anaerobic capacity is impaired in adults with GHD and improved with GH replacement. 
2.! Anaerobic capacity positively regulates physical function and QoL. 
3.! GH represses genes regulating oxidative metabolism in skeletal muscle  
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2! METHODS 
 
The major procedures undertaken for this body of work were: 
i)! Physical performance tests 
ii)! Physical function tests 
iii)! QoL assessment 
iv)! Body composition assessment 
v)! Gene expression profiling of skeletal muscle 
 
All protocols were approved by the Metro South Human Research Ethics Committee, Brisbane 
(HREC Reference number: HREC/12/QPAH/126) and carried out in accordance with Good 
Clinical Practice guidelines. This study is registered in The Australian New Zealand Clinical Trials 
Registry (number: ACTRN12615000046505). 
 
All procedures were performed in the Endocrine Testing Area of Princess Alexandra Hospital, with 
assistance of research nurses Kevin Carter and Tracy Grierson. I completed a clinical Bone 
Densitometry course to satisfy the requirements of radiation safety legislation for undertaking and 
analyzing DXA for body composition assessment. I performed the RNA extraction from muscle 
tissues under guidance of Dr. Johanna Barclay and Dr. Chris Morais at the School of Medicine, 
University of Queensland. Gene expression profiling of the muscle biopsy samples was undertaken 
at the Australian Genome Research Facility (AGRF), Melbourne and the University of Queensland 
Diamantina Institute, Brisbane. I performed statistical analysis of the data under guidance of Dr 
Anne Bernard and the analysis of gene expression data under guidance of Dr Stephen Rudd, 
Queensland Facility for Advanced Bioinformatics. I performed qRT-PCR experiments under 
guidance of Dr. Caroline Nelson at the School of Medicine, University of Queensland. 
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2.1! Subjects 
 
19 adults with GHD were recruited from Endocrine clinics at the Princess Alexandra Hospital, 
Brisbane. GHD was established by a peak GH response < 3µg/L to insulin-induced hypoglycemia 
or 3 or more pituitary hormone deficiencies with a subnormal IGF-I level (171). Subjects with 
severe cardio-respiratory, liver or renal impairment, or malignancy were excluded. The majority of 
patients had coexisting anterior pituitary hormone deficiencies and they were placed on stable 
replacement therapies for at least 6 months prior to enrollment in the study. 13 healthy controls 
matched for age-, gender-, and body mass index (BMI) to the first 13 adults with GHD were 
recruited through advertisement in the hospital and university newsletter. 
 
2.2! Clinical trial material and randomization 
 
Recombinant human GH (Norditropin) and placebo were provided by Novo Nordisk, Australia. The 
random allocation sequences were computer-generated and concealed until the time of allocation. 
Novo Nordisk generated the allocation sequences for GH and placebo in identical matched 
packaging labeled with the allocation number. Dr. Johanna Barclay, who was not involved in 
measuring study outcomes or analyzing data, randomized participants to GH or placebo. 
Participants and trial staff were blinded to the interventions all times. 
 
2.3! Assessments 
 
The following assessments were undertaken over two consecutive days. After an overnight fast, 
subjects arrived at the test venue at 0800h. After arrival, height, weight, pulse and blood pressure 
were measured. Blood was collected for urea and electrolytes, full blood count, thyroid function 
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test, oestradiol or testosterone. 5mL blood was centrifuged and plasma was stored at -20°C for later 
measurement of IGF-I after unblinding. The reproducibility of Wingate, VO2max, Stair climb and 
Chair stand tests, and pedometry were assessed by measuring the CV and ICC in 5 healthy 
volunteers who undertook these tests on two separate occasions (see below). 
 
2.3.1! Physical performance tests 
 
2.3.1.1! Wingate Test 
 
The Wingate anaerobic test was used to assess anaerobic capacity. It is one of the most widely used 
tests and has been validated in various groups ranging from athletes to individuals with chronic 
disease (172). The test-retest reliability values (r) for the Wingate test have ranged between 0.89 
and 0.99 (173). It requires pedaling for 30 seconds at maximal speed against a constant force based 
on body weight. Figure 2.1 illustrates the power output profile over 30 seconds. Two variables are 
calculated: peak anaerobic power and mean anaerobic power. Peak anaerobic power is the highest 
mechanical power elicited during the test, and typically occurs within the first few seconds. Mean 
anaerobic power is defined as the average power sustained throughout the 30-second period. Peak 
anaerobic power is thought to reflect alactic process and mean anaerobic power, anaerobic 
glycolysis. 
 
For this thesis, the Wingate test was performed after an overnight fast as described by Bar-Or et al. 
(172) using a Monark ergometer (Monark Exercise AB, Vansbro, Sweden). The force was 
calculated as 0.075 kp per kg body weight. A 3-minute warm-up followed by a 5-minute rest period 
preceded the actual test. The actual testing consisted of subject performing a 15-second countdown 
phase, a 30-second all-out pedaling phase and a 2-minute active cooldown phase.  
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Setup 
 
Seat height is adjusted so that no more than 5 degree of knee flexion present when the leg is fully 
extended to ensure optimal riding condition. Stirrups are applied so that a pushing or pulling force 
can be exerted on the pedal throughout the full cycle. A polar heart rate monitor is placed around 
subject’s chest for heart rate recording.  
 
Warm up 
 
Each subject is given a 3-minute warm-up period on the Monark ergometer against light resistance 
interspersed with two 5-second ‘all-out sprints’ for the subjects to get a feel for the actual test.  
 
 
The actual test 
 
The conduct of the full test is controlled by the Monark software, with a 15-second countdown prior 
to test initiation and subsequent data collection. The participants pedal as fast as possible to achieve 
maximum cadence three seconds before the resistance is applied. All subjects are verbally 
encouraged to continue to pedal as fast as possible for the entire 30 seconds.  
 
Cool down phase 
 
This involves a 2-minute of pedaling (cooldown phase) against light resistance immediately after 
the test.  
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Data collection and analysis 
 
Power output per second is recorded by the Monark software. Peak anaerobic power and anaerobic 
capacity (mean anaerobic power) are calculated and recorded in watts (W). 
 
 
 
Figure 2.1 Power output over 30 seconds during the Wingate test 
 
 
 
 
 
The reproducibility of the Wingate test was assessed in 5 healthy volunteers. The data are shown in 
table 2.1. 
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Table 2.1 Reproducibility of measures of the Wingate test. 
 
Subject 1 2 3 4 5 
Peak anaerobic power 
(Watts)      
Week 1 792 460 463 591 652 
Week 2 817 486 480 629 696 
Mean 805 473 472 610 674 
SD 18 18 12 27 31 
CV (%) 2 4 3 4 5 
Mean CV (%) 4 
ICC 0.99 
Mean anaerobic power 
(Watts)      
Week 1 551 308.7 327.7 423 375 
Week 2 573 328 315 428 394 
Mean 562 318 321 426 385 
SD 16 14 9.0 3.5 13 
CV (%) 3 4 3 1 3 
Mean CV (%) 3 
ICC 0.99 
 
2.3.1.2! VO2max test 
 
The VO2max test measures aerobic capacity. VO2max or maximal oxygen consumption is an 
objective measure of endurance (174). It measures the body’s maximum capacity to transport and 
utilize oxygen during exercise for energy production (175). In the laboratory, aerobic capacity is 
assessed by measuring the peak oxygen uptake during an incremental exercise test. This test can be 
performed on a treadmill or cycle ergometer and oxygen uptake is measured by a metabolic 
monitor. 
 
Exercise testing guidelines (176, 177) recommend adapting a protocol to the study participants and 
adjusting the work increment so that the total duration of exercise test is maintained between 8-12 
minutes. 
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For this thesis, VO2max was determined using a Monark ergometer. Oxygen consumption (VO2), 
carbon dioxide production (VCO2) and ventilatory volumes are measured continuously by a 
metabolic monitor (ParvoMedics, UT, USA). This machine uses infrared CO2 and paramagnetic O2 
analyzers and a pneumotachograph. Calibration against standard gases (16% O2 and 4% CO2), 
volume (3 litre), operating temperature, humidity and barometric pressure is performed immediately 
before each test.  
 
Toe stirrups are fitted and seat height is adjusted as described in the section ‘Wingate test’. Polar 
heart rate monitor is placed around the chest of the subject. A work rate is set at 40W and increased 
by 10W every minute until exhaustion. Subjects are encouraged verbally to maximize effort. VO2 
values are averaged for each 15-second period and highest value is recorded as VO2max. It is 
expressed in absolute values (L/min) and also in ml/min/kg. 
 
The reproducibility of the VO2max test in 5 healthy volunteers is shown in table 2.2. 
 
Table 2.2 Reproducibility of VO2max Test.  
 
Subject 1 2 3 4 5 
Week 1 (ml/kg/min) 47 32 33 43 29 
Week 2 (ml/kg/min) 50 30 36 42 29 
Mean 48 31 34 42 29 
SD 2.6 1.6 2 0.3 0.4 
CV (%) 5 5 6 1 1 
Mean CV (%) 4 
ICC 0.96 
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2.3.2! Physical function tests 
 
The functional significance of anaerobic capacity was evaluated by the stair climb test, chair stand 
test and aerobic capacity by 7-day pedometry.  
 
 
 
2.3.2.1! Stair climb test 
 
The stair climb test is widely used for the assessment of physical function and leg muscle power 
(178-180). Various protocols have been developed for different populations, to measure the time to 
ascend a set number of stairs or the step count for a set period of time (179).  
 
The stair climb test in this study measures the time to ascend 4 flights of stairs totaling 48 steps 
(step height 17cm). The time is recorded to the nearest 0.001 second, using a switch mat timing 
system (TAG Heuer HL440 Minitimer, TAGHeuer Professional Timing, La Chaux-De-Fonds, 
Switzerland). The participants are instructed to climb the stairs as fast as possible one step at a time. 
The test is performed three times with each occasion separated by a rest period of 5 minutes. The 
best of three readings is included for data analysis. 
 
The reproducibility of the stair climb test in 5 healthy volunteers is shown in table 2.3. 
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Table 2.3 Reproducibility of the stair climb test.  
 
Subjects 1 2 3 4 5 
Week 1 (sec) 13 13 18 13 16 
Week 2 (sec) 12 13 18 13 15 
Mean 12 13 18 13 15 
SD 0.5 0.4 0.6 0.4 0.9 
CV (%) 4 3 4 3 6 
Mean CV (%) 4 
ICC 0.97 
 
 
2.3.2.2! Chair stand test 
 
The chair stand test is a validated test to assess functional performance (181). It measures the 
number of times one can stand up and sit down in 30 seconds from a fully seated position in a chair. 
 
 
Participants are seated in the middle of chair with their arms crossed and held against the chest. The 
chair dimensions are 43cm height and 47.5 cm depth, with a fixed 4-legged base. It is placed 
against the wall to restrict movement during the test. The time is recorded by a stopwatch and 
repetitions are counted by an electronic counter. The participants are instructed to rise to a full stand 
with knees fully extended and then return back to a fully seated position as many times as possible 
within 30-second period. The total number of stands executed correctly within 30-second period is 
recorded (more than halfway up at the end of 30 second is counted as a full stand). The test is 
repeated three times separated by a 5-min rest period and the best reading out of three is used for 
data analysis. 
 
The reproducibility of the chair stand test in 5 healthy volunteers is shown in table 2.4. 
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Table 2.4 Reproducibility of the chair stand test.  
 
Subject 1 2 3 4 5 
      
Week 1 (Repetitions) 32 39 17 22 18 
Week 2 (Repetitions) 39 42 22 27 19 
Mean 36 41 20 25 19 
SD 4.6 2.1 3.5 3.5 0.7 
CV (%) 14 5 18 14 4 
Mean CV (%) 11 
ICC 0.95 
 
 
2.3.2.3! Pedometry 
 
Pedometry is a simple, inexpensive and user-friendly research tool, for the objective assessment of 
habitual physical activity in healthy and in patients with chronic disease (182). It measures the 
number of steps per day (183). In this project Kenz activity monitor (Kenz Lifecorder, Suzuken Co., 
Ltd., Nagoya, Aichi, Japan) was used to measure daily step count for 7 consecutive days. It has an 
intramodel reliability of 0.998 and absolute accuracy of +/- 3% (184). Participants are instructed to 
wear the Kenz activity monitor on their waist belt continuously for 7 days, which is sufficient to 
provide a reliable estimate of monthly activity in adults (185). The total daily physical activity (i.e. 
steps) data are downloaded to a computer using the Kenz Lifecorder software and the average is 
reported as the daily step count. 
 
The reproducibility of 7-day pedometry in 5 healthy volunteers is shown in table 2.5. 
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Table 2.5 Reproducibility of 7-day pedometry.  
 
Subject 1 2 3 4 5 
      
Week 1 (Steps) 68429 74369 39718 21998 70069 
Week 2 (Steps) 62975 67702 46556 23506 70820 
Mean 65702 71035.5 43137 22752 70444.5 
SD 3857 4714 4835 1066 531 
CV (%) 6% 7% 11% 5% 1% 
Mean CV (%) 6 
ICC 0.98 
 
 
2.3.3! Quality of life assessment 
 
QoL was assessed by QoL-AGHDA (Quality of Life Assessment of GH Deficiency in Adults) 
questionnaire, a research tool specifically validated in adults with GHD, to determine whether there 
was an association between anaerobic capacity and QoL in adults with GHD (186, 187). The QoL-
AGHDA questionnaire contains 25 items with a ‘yes/no’ response format. Each positive (yes) 
response is given a score of 1, allowing scores to range from 0 to 25. High scores indicate poor 
QoL. Out of 25 questions in the AGHDA questionnaire, 8 questions directed at energy and vitality 
domains are used in a sub-analysis to assess GH effects on energy metabolism. The remaining 17 
questions directed at QoL-domains such as social isolation, memory and concentration, emotional 
reactions and sleep are grouped together as non-energy and vitality domain and analyzed separately.  
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2.3.4! Body composition assessment 
 
Body composition was assessed by DXA using a Hologic absorptiometer (Model QDR 4500A, S/N 
45432, Software version 12.6) before and after GH therapy to allow correction of anaerobic power 
and VO2max for increases in LBM that were expected to occur.  
 
2.3.5! Muscle biopsy in GHD group 
 
Muscle biopsies were undertaken in adults with GHD using 5mm Bergstrom needle. The biopsy is 
obtained from vastus lateralis 12cm above the upper border of patella. The skin and subcutaneous 
tissue is infiltrated with 1% lignocaine without adrenaline. The depth of fascia overlying muscle is 
defined using a 25-gauge needle tip. A size 11 scalpel is used to puncture the skin, subcutaneous 
tissue and muscle fascia. Using a suction technique, Bergstrom needle is used to yield 100-150mg 
of muscle. Muscle tissue is immediately frozen in liquid nitrogen and stored at -80°C.  
 
2.3.6! RNA extraction  
 
During the 1-month placebo controlled trial, total RNA was isolated from snap-frozen muscle 
biopsies using the TRIzol Reagent (Life Technologies Inc., Gaithersburg, Maryland 20884, USA) 
according to the manufacturer’s instructions as follows:  
 
1.! Homogenizing samples and phase separation 
1ml of TRIzol reagent is added to 50-80mg of muscle tissue and the sample is homogenized with a 
rotor stator. Homogenized sample is incubated for 5 min at room temperature to permit complete 
dissociation of the nucleoprotein complex. 0.2mL of chloroform is added and the sample is 
centrifuged at 12000x g for 15 minutes. The mixture separates into a lower red phenol-chloroform 
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phase, an interphase, and a colorless upper aqueous phase, which contains RNA. The upper aqueous 
is removed and placed in a separate tube for RNA precipitation. 
2.! RNA precipitation 
0.5mL of 100% isopropanol is added to the aqueous phase. The mixture is incubated at room 
temperature for 10 minutes followed by centrifugation at 12000x g for 10 minutes. The RNA forms 
a pellet on the side and bottom of the tube. 
3.! RNA wash 
The supernatant from the tube is removed, leaving only the RNA pellet. The pellet is washed with 
1mL 75% ethanol and centrifuged at 7500x g for 5 minutes. The wash is discarded and the RNA 
pellet is air dried for 5-10 minutes. 
4.! RNA resuspension 
The RNA pellet is resuspended in 30µL of RNase-free water and incubated in a heat block set at 
55°C for 10 minutes. The RNA is stored at -80°C. 
5.! RNA quality assessment 
The quality of the RNA samples is determined using the Agilent RNA 6000 Nano Kit on the 2100 
Bioanalyzer (Agilent, Amstelveen, The Netherlands). Only total RNA samples with a RNA 
integrity number higher than seven are included for further analysis. 
 
During the open label study, total RNA was isolated from snap-frozen muscle biopsies using 
RNeasy fibrous tissue extraction kit (Qiagen, Valencia, USA) according to the manufacturer’s 
instructions as follows:  
1.! 30mg muscle is disrupted and homogenized with rotor-stator in the presence of 300µl of 
Buffer RLT. 
2.! 590µl RNase-free water is added to the lysate. Then 10µl of proteinase K solution is added 
and mixed thoroughly. 
3.! Lysate is incubated at 55°C for 10 minutes and then centrifuged for 3 minutes at 10,000xg. 
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4.! The supernatant is transferred into a new microcentrifuge tube. 
5.! 0.5 volume of 100% ethanol (usually 450µl) is added to the cleared lysate and mixed well 
by pipetting. 
6.! 700µl of the sample is transferred to an RNeasy Mini spin column placed in a 2ml collection 
tube and centrifuged for 15 s at ≥ 8000xg. The flow-through is discarded. This step is 
repeated using the remainder of the sample. 
7.! 350µl Buffer RW1 is added to the RNeasy Spin column and centrifuged for 15 s ≥8000xg to 
wash the membrane. The flow-through is discarded. 
8.! 10µl DNase I stock solution is added to 70µl Buffer RDD, mixed by gently inverting the 
tube, and centrifuged briefly to collect residual liquid from the sides of the tube.   
9.! The DNase I incubation mix (80µl) is added directly to the RNeasy spin column membrane, 
and placed on the benchtop for 15 min.   
10.! 350µl Buffer RW1 is added to the RNeasy spin column and centrifuged for 15 s at ≥8000xg 
at 20–25°C. The flow-through is discarded. 
11.!500µl Buffer RPE is added to the RNeasy spin column and centrifuged at 20–25°C for 15 s 
at ≥8000xg to wash the membrane. The flow-through is discarded. 
12.!500 µl Buffer RPE is added to the RNeasy spin column and centrifuged at 20–25°C for 2 
min at ≥8000xg to wash the membrane.   
13.!The RNeasy spin column is placed in a new 1.5 ml collection tube. 30µl RNase-free water is 
added directly to the RNeasy spin column membrane and centrifuged for 1 min at ≥8000xg 
to elute the RNA. The RNA is stored at -80°C. 
14.!The quality of the RNA samples is determined using the Agilent RNA 6000 Nano Kit on the 
2100 Bioanalyzer (Agilent, Amstelveen, The Netherlands). Only total RNA samples with a 
RNA integrity number higher than seven are included for further analysis. 
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2.3.7! Gene expression analysis 
 
Microarray experiments were undertaken separately for the 1 month and 6 month studies. Samples 
for the 1-month study were processed at the Australian Genome Research Facility (Melbourne, 
Australia) and for the 6-month study at the University of Queensland Diamantina Institute 
(Brisbane, Australia). For both experiments, the RNA samples were biotinylated and amplified 
using the Illumina® TotalPrep™ RNA Amplification Kit (Ambion, Austin, TX, USA) according to 
the manufacturer’s instructions with a standardized input amount of 500ng. 
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3! ANAEROBIC CAPACITY IN ADULTS WITH GROWTH 
HORMONE DEFICIENCY 
 
3.1! Introduction 
 
 
Energy derived from the aerobic energy system is used at rest and during endurance exercise. 
Whereas the AES powers intensive activity of short-term duration and it is also important for the 
initiation of all biological activities including activities of daily living such as rising from a chair, 
climbing stairs, rushing for a bus (5). Thus it is conceivable that impairment of anaerobic capacity 
leads to the perception of increased fatigue during the execution of ordinary activities of daily 
living, a symptom commonly observed in adults with GHD (152). 
 
 
There is strong evidence from studies in adults with GHD that muscle strength and aerobic capacity 
are impaired in GHD and restored to near normal with GH replacement over a period of few months 
(3, 6). Whether anaerobic capacity is impaired in GHD or GH regulates the AES has not been 
studied. There is emerging evidence that GH may have a regulatory role in anaerobic metabolism 
(7, 8). In a gene expression study involving adults with GHD, GH therapy led to changes that may 
favour non-oxidative glycolysis for ATP production in skeletal muscle (7). In a study involving 
recreational athletes, short duration GH therapy significantly improved anaerobic capacity (8). 
However, this study was undertaken in GH sufficient healthy adults using a supraphysiological dose 
of GH and the physiological significance of these findings is unclear. 
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The aims of this section of work were to assess whether anaerobic exercise capacity is impaired in 
adults with GHD and to evaluate its functional relevance. 
 
 
3.2! Methods 
 
3.2.1! Subjects 
 
13 hypopituitary adults with GHD and 13 age-, gender-, and BMI-matched normal adults were 
recruited. The causes of pituitary deficiencies and hormone replacements are summarized in the 
Table 3.1. None of the hypopituitary patients had been previously replaced with GH except for two 
subjects. In these patients, GH therapy was stopped at least 3 months before recruitment.  
 
3.2.2! Study design 
 
This was a cross-sectional comparison of anaerobic capacity, aerobic capacity, physical function, 
body composition and QoL. Subjects attended the test venue on 2 consecutive days for the 
assessments after an overnight fast.  
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Table 3.1 Causes of pituitary deficiency and pituitary hormone replacement therapies in 13 
subjects with GHD.  
H, hydrocortisone; C, cortisone acetate; P, prednisone; T4, thyroxine; E2, estradiol; T, testosterone; 
D, desmopressin 
 
Patient 
No. 
Age Gender Diagnosis Hormone 
Replacement 
1 38 F Cushing’s disease H, T4, E2, D 
2 24 F Septo-optic dysplasia H, T4, E2 
3 38 F Macroprolactinoma C, T4, E2, D 
4 46 F Silent corticotroph 
macroadenoma 
H, T4 
5 60 F Panhypopituitarism, Empty 
sella 
C, T4 
6 57 F Non-functioning 
macroadenoma 
T4 
7 52 F Cushing’s disease C, T4, E2 
8 58 M Cushing’s disease C, T, T4 
9 49 F Macroprolactinoma H, T4, E2, D 
10 39 F Glioma P, T4, E2 
11 46 F Cushing’s disease P, T4, E2, D 
12 48 F Non-functioning 
macroadenoma 
H 
13 58 F Rathke’s cleft cyst C, T4 
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3.2.3! Assessments 
 
 
The detailed protocols of assessments are described in the Chapter 2. Anaerobic and aerobic 
capacities were assessed by the Wingate test and VO2max test respectively. The stair climb test and 
chair stand test were used as the functional assessments of anaerobic capacity, and 7-day pedometry 
as of aerobic capacity. DXA scan was performed to measure LBM and fat mass. QoL was assessed 
by QoL-AGHDA questionnaire. 
 
 
 
 
3.3! Statistical analysis 
 
Statistical analysis was performed with IBM SPSS statistics software (Version 22, Chicago, IL, 
USA). Results are reported as mean ± SEM. Comparisons between normal and GH deficient groups 
were performed with unpaired t test. Associations were explored with simple linear regressions. 
Multiple linear regression analyses were used to determine the independent predictors among age, 
gender, LBM and GHD of peak and mean anaerobic power, and VO2max; and independent 
predictors among peak and mean anaerobic power, VO2max, age, gender, LBM and GHD of 
functional measures. A p value of less than 0.05 was considered statistically significant. 
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3.4! Results 
 
 
Age, gender and the BMI of 13 normal and 13 adults with GHD are shown in Table 3.2. There were 
no significant differences in age and BMI between the two groups. Mean fat mass tended to be 
higher and LBM lower in adults with GHD but the differences were not statistically significant. 
 
 
LBM significantly correlated with peak and mean anaerobic power, and VO2max in the combined 
groups of normal and adults with GHD (Figure 3.1). For data analysis, peak and mean anaerobic 
power, and VO2max are corrected for LBM and expressed as watts.kgLBM-1 and ml.kgLBM-1.min-1 
respectively.  
 
 
3.4.1! Physical Performance (Table 3.2) 
 
 
Mean anaerobic power (p<0.05) and VO2max (<0.01) were lower in adults with GHD compared to 
normal adults. These measures remained significantly lower when corrected for LBM in adults with 
GHD (p<0.05 and p<0.01 respectively). The mean anaerobic power and VO2max were 18% and 
20% lower in GH deficient adults respectively.  
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Table 3.2 Baseline characteristics, performance tests, functional measures and quality of life 
in 13 adults with GHD and 13 normal subjects.  
All values are shown as the mean ± SEM. NS, Not significant. 
 GHD Normal p value 
M:F 1:12 1:12  
Age (years) 45.3 ± 3.2 43.7 ± 3.1 NS 
BMI (kg.m-2) 27.0 ± 1.4 26.0 ± 1.1 NS 
LBM (kg) 41.8 ± 1.9 44.1 ± 1.5 NS 
Fat mass (kg) 26.8 ± 2.3 21.9 ± 2.1 NS 
Peak anaerobic power (W) 424 ± 33 473 ± 22 NS 
Peak anaerobic power 
(W.kgLBM-1) 10.0 ± 0.4 10.7 ± 0.3 NS 
Mean anaerobic power (W) 246 ± 22 312 ± 17 <0.05 
Mean anaerobic power 
(W.kgLBM-1) 5.8 ± 0.4 7.1 ± 0.3 <0.05 
VO2max (L.min-1) 1.6 ± 0.1 2.1 ± 0.1 <0.01 
VO2max                   
(ml.min-1.kgLBM-1) 37.2 ± 1.5 46.7 ± 2.9 <0.01 
Stair climb test      
(Seconds) 19.4 ± 0.7 16.5 ± 0.7 <0.01 
Chair stand test 
(Repetitions) 19.2 ± 1.2 25.5 ± 2.1 <0.01 
Pedometry                   
(Steps per day) 6655 ± 634 9565 ± 668 <0.01 
QoL-AGHDA score  16.6 ± 1.6 2.1 ± 0.8 <0.0001 
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Figure 3.1 Relationship between LBM and peak anaerobic power (Panel A), mean anaerobic 
power (Panel B) and VO2max (Panel C) in the combined groups of 13 adults with GHD (!) 
and matched normal subjects ("). 
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3.4.2! Physical function (Table 3.2) 
 
 
The functional relevance of anaerobic capacity was assessed by tasks that were completed over 15 
to 30 seconds, the time course of physical activity that is mainly subserved by the AES. In the stair 
climb test, adults with GHD took a significantly longer time (p<0.01) to complete the task of 
climbing 4-flights of stairs than normal adults. In the chair stand test, number of repetitions 
performed in 30 seconds was approximately 30% lower (p<0.01) in adults with GHD. In order to 
assess the functional relevance of aerobic capacity, 7-day pedometry was performed. The average 
daily step count was in adults with GHD was approximately 30% lower (p<0.01) compared to 
normal subjects. 
 
 
3.4.3! Quality of life (Table 3.2) 
 
 
Mean QoL-AGHDA scores were significantly higher in GH-deficient adults, indicating a worse 
QoL (p<0.0001).  
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3.4.4! Relationship between physical performance measures, functional measures and quality 
of life (Figure 3.2) 
 
 
 
Relationships between performance measures, functional measures and QoL were analyzed by 
simple linear regression. Mean anaerobic power significantly correlated with the stair climb 
performance (R2= 0.7, p<0.0001, Figure 3.2 Panel A) and pedometry (R2= 0.3, p<0.01, Figure 3.2 
Panel C). VO2max correlated significantly with the stair climb performance (R2= 0.3, p<0.01, 
Figure 3.2 Panel B) and pedometry (R2= 0.5, p<0.0001, Figure 3.2 Panel D). The relationship 
between stair climb performance and mean anaerobic power was stronger than with VO2max. Mean 
anaerobic power accounted for 70% while the VO2max only 30% of variation in the stair climb 
performance.  
 
 
 
The relationship between pedometry and VO2max was stronger than with mean anaerobic power. 
VO2max accounted for 50% while the mean anaerobic power only 30% of variation in pedometry. 
The relationship between mean anaerobic power and chair stand performance was not significant as 
was the case for VO2max. Both mean anaerobic power (R2= 0.3, p<0.01) and VO2max (R2= 0.2, 
p<0.05) were inversely related with QoL-AGHDA score. 
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Figure 3.2 Relationship between stair climb performance and anaerobic power (Panel A) and 
VO2max (Panel B), and between daily step counts quantified by pedometry and anaerobic 
power (Panel C) and VO2max (Panel D) in the combined groups of 13 adults with GHD (!) 
and matched normal subjects ("). 
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3.4.5! Predictors of physical performance measures, functional measures and quality of life 
 
Multiple regression analyses were performed to determine significant predictors of physical 
performance measures, functional measures and QoL. For mean anaerobic power, GH status, age, 
gender and LBM were significant independent determinants (p<0.05) while only LBM significantly 
and independently predicted peak anaerobic power (p<0.05) (Table 3.3 and 3.4). These four 
variables were also significant determinants of VO2max (p<0.05) (Table 3.5).  
 
 
For stair climbing, with peak and mean anaerobic power, VO2max, GH status, age, gender and 
LBM as independent variables, only mean anaerobic power (p<0.01) emerged as the significant 
determinant (Table 3.6). For chair stand performance, GH status (p<0.05) was an independent 
predictor (Table 3.7); while for pedometry, only VO2max (p=0.05) was an independent predictor at 
a borderline level of significance (Table 3.8).  
 
 
For QoL, with peak and mean anaerobic power, VO2max, GH status, age, gender and LBM as 
independent variables, GH status (p<0.001) and mean anaerobic power (p<0.05) emerged as 
significant determinants (Table 3.9). 
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Table 3.3 Linear regression model of predictors of mean anaerobic power 
 
 
Table 3.4 Linear regression model of predictors of peak anaerobic power 
 
 
Table 3.5 Linear regression model of predictors of VO2max 
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Table 3.6 Linear regression model of predictors of stair climb test 
 
 
 
 
 
 
Table 3.7 Linear regression model of predictors of chair stand test 
 
 
 
 84 
 
 
 
Table 3.8 Linear regression model of predictors of pedometry 
 
 
 
Table 3.9 Linear regression model of predictors of quality of life 
 
 
 85 
3.5! Discussion 
 
This study compared physical performance measures, functional measures and QoL between adults 
with GHD and age-, gender-, and BMI-matched normal adults. GH-deficient adults had lower 
anaerobic and aerobic capacities, functional capacities and QoL compared to normal adults. Mean 
anaerobic power and VO2max significantly correlated with stair climb performance, daily step 
count and QoL. GH status was an independent predictor of mean anaerobic power, VO2max and 
QoL. Mean anaerobic power independently predicted stair climb performance and QoL, while 
VO2max predicted daily step count. 
 
Adults with GHD had a lower LBM and higher fat mass. Although these findings did not reach 
statistical significance, they are consistent with the current literature (188) and likely to reflect the 
relatively small sample size. LBM was a positive determinant of peak and mean anaerobic power, 
and VO2max; hence these measures were corrected for LBM and expressed as watts.kgLBM-1 and 
ml.min-1.kgLBM-1 respectively. In this study, anaerobic and aerobic capacities were reduced in 
adults with GHD even after correcting for LBM. These findings indicate that the quantity and 
quality of skeletal muscle are reduced in GHD. 
 
This study provides the first evidence that anaerobic capacity of adults with GHD is subnormal. The 
observation that GH status is an independent predictor of anaerobic capacity suggests that GH 
regulates the AES. This finding supports a finding in recreational athletes that anaerobic sprint 
capacity improves after 8 weeks of GH therapy (8). Anaerobic capacity is dependent on strength 
and energy required for work performance. The improvement of anaerobic sprint capacity in 
athletes occurred without an increase in muscle strength (8) suggesting mediation by metabolic 
rather than anabolic mechanisms.  The metabolic energy requirement during a 30-second Wingate 
test is predominantly met by the phosphocreatine stores (pre-formed ATP) for the first 10 seconds 
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and by anaerobic glycolysis thereafter (189). The authors did not report a sub-analysis of the 
Wingate profile. It is therefore unclear whether the improvement in sprint capacity occurred by an 
increase in the power output throughout the 30-second period or the peak component. In the present 
cross-sectional study, adults with GHD exhibited lower mean anaerobic power, but not the peak 
anaerobic power. These findings suggest that the improvement in anaerobic capacity observed in 
athletes following GH treatment was related to the stimulation of anaerobic glycolysis.  
 
GH stimulates whole body lipid oxidation and resting energy expenditure in healthy subjects (113, 
120, 121) and in adults with GHD (122-124). It has been assumed that these whole body effects 
reflect the actions of GH in skeletal muscle. However, there is emerging evidence that metabolic 
actions of GH are tissue specific and whole body changes may not reflect those in skeletal muscle. 
Tollet-Egnell et al. reported down regulation of genes governing lipid oxidation in skeletal muscle 
of rats following GH treatment (126). Sjogren et al. found that GH down regulated genes in skeletal 
muscle involved in lipid metabolism, the TCA cycle activity and the mitochondrial respiration (7). 
These findings suggest that GH inhibits aerobic metabolism in favor of non-oxidative (anaerobic) 
pathways for ATP synthesis. These findings provide a plausible explanation for the loss of 
anaerobic capacity and function in GH deficiency. 
 
The present study confirms previous findings that aerobic capacity is impaired in adults with GHD 
(6, 28, 133-135). The underlying mechanisms responsible for the impaired aerobic capacity are 
multifactorial. Oxygen delivery to muscles depends on cardiac function, lung capacity and oxygen 
carrying capacity of blood. Adults with GHD have impaired cardiac function (137), diminished 
lung capacity (138) and reduced red cell mass (139), factors that collectively reduce oxygen 
delivery to exercising muscles. These deficits lead to a decrease in oxygen supply to a reduced 
muscle mass explaining impaired aerobic capacity in adults with GHD. 
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A novel aspect of this study is the investigation of functional relevance of anaerobic and aerobic 
capacities in adults with GHD. There are no previous studies investigating the relationship between 
physical performance and functional assessment nor their relationships to QoL in GHD.  Because 
anaerobic energy initiates all movement and powers short burst of intense activities, it was 
postulated that its physical functional relevance could be reflected in the stair climb test and chair 
stand test performed over a brief duration. In contrast, the functional relevance of aerobic energy 
system, which supports low intensity prolonged activities, would be reflected in daily pedometry. 
Adults with GHD on average took 18% longer to climb 4 flights of stairs, performed 30% less 
number of chair stand repetitions and had 30% lower daily step count. In a multiple regression 
analysis, mean anaerobic power independently predicted the stair climb performance supporting the 
hypothesis that stair climbing relies predominantly on the AES. There was no significant 
relationship observed between chair stand performance and mean anaerobic power or VO2max.  In 
contrast VO2max was the major predictor of weekly pedometry, suggesting that daily walking is 
dependent on the aerobic energy system. These data support results by Izawa et al., who reported a 
positive correlation between daily walking activity and aerobic capacity in patients with chronic 
heart failure (190). Thus the anaerobic and aerobic energy systems subserve distinct aspects of 
physical function of daily living that are regulated by the GH. 
 
QoL-AGHDA scores were significantly higher in adults with GHD compared to normal adults, 
indicating a worse QoL, in agreement with previous studies (150, 152, 153, 191).  Both anaerobic 
power and VO2max were inversely related with QoL-AGHDA score. However, in a multivariate 
analysis, only GH status and anaerobic power independently predicted QoL. Although these 
findings do not prove causality, they suggest a significant role of the AES in maintaining a normal 
QoL in adults with GHD. 
 This study has a number of limitations. It was undertaken in a group of subjects who were 
predominantly women. It is likely that the finding of impaired anaerobic capacity in GHD apply to 
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both men and women. Thyroid and adrenal hormones are among several hormones that influence 
the AES in addition to GH (192-194). In this study, most of the subjects with GHD harbored 
coexisting anterior pituitary hormone deficiencies with four subjects having a history of Cushing’s 
disease. These subjects were replaced with thyroid, adrenal and gonadal hormones in accordance 
with standard endocrine practice. Although the groups were matched for gender, age and BMI, a 
possibility that impairment of anaerobic capacity arose from suboptimal replacement therapies, the 
consequences of chronic hypercortisolism or non-hormone related factors can not be ruled out. One 
such confounder is the impact of a chronic suboptimal level of health on the performance variables. 
A prospective GH intervention study is required to confirm whether GH improves anaerobic 
capacity in adults with GHD. 
 
In summary, anaerobic capacity, aerobic capacity, stair climb and chair stand performance, weekly 
pedometry and QoL are reduced in adults with GHD. GH status is an independent determinant of 
anaerobic and aerobic capacity. Anaerobic capacity independently predicts stair climb performance 
but not daily step count, which is determined by aerobic capacity. GH status and anaerobic capacity 
are independent determinants of QoL.  
 
In conclusion, GH regulates the AES. Stair climb is a functional measure of anaerobic capacity.  
The AES is a significant contributor to QoL in patients with GHD. 
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4! EFFECTS OF GH ON ANAEROBIC CAPACITY AND 
PHYSICAL FUNCTION 
 
4.1! Introduction 
 
There is emerging evidence that GH plays a role in the regulation of the AES. In adults with GH 
deficiency, Sjogren et al. found that short-term GH replacement repressed genes regulating aerobic 
metabolic pathways in skeletal muscle, favoring anaerobic energy production (7). In recreational 
athletes, Meinhardt et al. reported that GH treatment improved sprint capacity without affecting 
muscle strength suggesting facilitation by energy metabolism rather by muscle anabolism (8). This 
study however, was undertaken in GH-sufficient subjects treated with a supraphysiological dose of 
GH. As reported in Chapter 3, anaerobic capacity is reduced in adults with GHD compared to age, 
gender and BMI matched control subjects. As the GHD group comprised of subjects with organic 
hypopituitarism, subnormal anaerobic capacity may have arisen from suboptimal replacement of 
other pituitary hormone therapies such as thyroid or adrenal hormone or concurrent chronic 
suboptimal health rather than GHD alone. This study investigated whether physiological 
replacement of GH improves anaerobic capacity and physical function dependent on the AES in 
adults with GHD.  
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4.2! Material and Methods 
 
4.2.1! Subjects 
 
19 hypopituitary adults (15 females and 4 males, mean ± SD age: 46.2 ± 10.3 (range 24-60)) with 
GHD were recruited. The causes of pituitary deficiencies and hormone replacements are 
summarized in Table 4.1. None of the hypopituitary patients had been previously replaced with GH 
except for three subjects. In one patient, GH therapy was stopped 3 months before the recruitment. 
The other two patients had not received GH for five years.  
 
Table 4.1 Causes of pituitary deficiency and pituitary hormone replacement therapies in 19 
subjects with GHD.  
F, female; M, male; H, hydrocortisone; C, cortisone acetate; P, prednisone; T4, thyroxine; E2, 
estradiol; T, testosterone; D, desmopressin 
 
Patient 
No. 
Age Gender Diagnosis Surgery/ 
Irradiation 
Hormone 
Replacement 
1 38 F Cushing’s disease Yes/No H, T4, E2, D 
2 24 F Septo-optic dysplasia No/No H, T4, E2 
3 38 F Macroprolactinoma Yes/No C, T4, E2, D 
4 46 F Silent corticotroph 
macroadenoma 
Yes/No H, T4 
5 60 F Panhypopituitarism, 
Empty sella 
No/No C, T4 
6 57 F Non-functioning Yes/No T4 
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macroadenoma 
7 59 M Non-functioning 
macroadenoma 
Yes/Yes C, T4, T, D 
8 58 M Cushing’s disease Yes/Yes C, T, T4 
9 49 F Macroprolactinoma Yes/No H, T4, E2, D 
10 39 F Glioma Yes/Yes P, T4, E2 
11 46 F Cushing’s disease Yes/Yes P, T4, E2, D 
12 48 F Non-functioning 
macroadenoma 
Yes/No H 
13 58 F Rathke’s cleft cyst Yes/No C, T4 
14 38 F Non-functioning 
macroadenoma 
Yes/No T4 
15 41 F Craniopharyngioma Yes/No H, T4, E2 
16 32 M Non-functioning 
macroadenoma 
Yes/No H, T4, T, D 
17 44 M Non-functioning 
macroadenoma 
Yes/No H, T4, T 
18 58 F Macroprolactinoma Yes/Yes P, T4 
19 52 F Cushing’s disease Yes/Yes C, T4, E2 
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4.2.2! Study design 
 
This is a two-phase design involving (a) a 2-month double-blind placebo-controlled GH with a 
crossover at 1-month, followed by (b) an open-label active treatment phase of 6 months (Figure 
4.1).  GH effects on energy metabolism in skeletal muscle are detected as early as 2 weeks (7), 
however, an increase in muscle mass is seen only after several months of treatment (3). The 
rationale for the 1-month and 6-month GH treatment is to separate the early effects of GH on the 
AES from the later anabolic effects on muscle mass and strength.  
 
 
 
Figure 4.1 Study design: 2-month double blind placebo controlled GH study with a crossover 
at 1-month, followed by an open label active treatment for 6 months. 
Assessments of aerobic capacity, anaerobic capacity, physical function, body composition and 
quality of life are undertaken at time points indicated by arrows. GHD, growth hormone deficiency; 
GH, growth hormone; PL, placebo 
 
 
 
During the placebo-controlled study, GH (Norditropin; NovoNordisk, Denmark) replacement was 
initiated at a dose of 0.2mg/day for the first week, increased to 0.4 mg for the second week and to 
0.5 mg, the target dose for the last two weeks. The gradual stepwise regimen was implemented to 
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reduce side effects. During the open-label study, the GH dose was titrated individually to maintain 
serum IGFI concentrations in the adult normal reference range (9 to 33 nmol/L). Assessments for 
anaerobic capacity, aerobic capacity, physical function, body composition and QoL were 
undertaken at baseline and at the end of each treatment phase. Subjects attended the test venue on 
two consecutive days on each occasion after an overnight fast.  
 
4.2.3! Assessments 
 
The detailed protocols of assessments are described in the section 2. Anaerobic and aerobic 
capacities were assessed by the Wingate test and VO2max test respectively. The stair climb test and 
chair stand test were used as the functional assessments of anaerobic capacity, and 7-day pedometry 
as of aerobic capacity. DXA scan was performed to measure LBM and fat mass. QoL was assessed 
by QoL-AGHDA questionnaire. 
 
4.3! Statistical analysis 
 
This study was powered to detect a significant change in anaerobic and aerobic capacity. The 
sample size was based on anaerobic capacity data from previous study in recreational athletes (8) 
and aerobic performance data from Cuneo et al. in adults with GHD (133). A sample of 15 is 
required to show a 5% improvement in Wingate power and 18 for a 15% improvement in VO2max 
at a 0.05 significance level with 80% power. Statistical analysis was performed with IBM SPSS 
Statistics Software (Version 22, Chicago, IL, USA). Results are reported as mean ± SEM. In the 2-
month placebo controlled study, comparison between GH and placebo groups were performed with 
analysis of variance for repeated measures (ANOVA). The data were analysed for carryover effects 
using a linear mixed model analysis by studying the effect of interaction between the treatment 
order (GH/Placebo or Placebo/GH) and treatment itself on outcome measures. In the 6-month open 
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label study, the effects of GH on outcome measures were compared with the baseline measurements 
and 1-month placebo treatment using a paired t test based on a review of controlled GH trials that 
contain a placebo arm in which functional (physical function and QoL) outcomes were measured on 
more than two occasions. These trials showed that a placebo effect if present at the first evaluation 
does not change significantly on repeat evaluation (8, 148, 195). Based on the results of the cross-
section study described in Chapter 3 (196) and directional hypothesis of this trial, one-tailed t-test 
was used to assess the effects of GH. Multiple regression analysis was performed to assess 
independent predictors of QoL amongst age, gender, LBM, measures of physical performance and 
physical function. A p value of less than 0.05 was considered statistically significant. 
 
4.4! Results 
 
Of the 19 subjects enrolled, one withdrew during the open-label study due to GH related side effects 
(see below). One patient lost significant weight of 13kg during the study from lifestyle change. By 
contrast the mean change in body weight for the remaining study cohort (n=18) during the trial was 
1.3 ± 0.5 kg. This patient was not included in the analysis, which comprised 18 of the subjects 
recruited into the study. 
 
4.4.1! IGFI concentration (Table 4.2) 
 
Mean IGFI concentration rose significantly (p<0.0001) in response to GH administration during the 
placebo-controlled and open phase. During the open phase, the GH dose was titrated to maintain the 
IGF-I concentration in the adult normal range and in accordance with side effects (see below), 
resulting in a fall of the mean GH dose from 0.5 to 0.37 mg/day. 
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Table 4.2 Effects of 1-month and 6-month GH replacement on IGFI concentrations, body composition, physical performance, physical 
function and QoL.  
LBM, lean body mass; VO2max, maximal oxygen consumption; QoL, quality of life, NS, not significant. All values are shown as the mean ± SEM. 
aGH vs. Placebo during placebo-controlled study, bGH vs. Baseline during open label study. 
 
 
 1-month placebo-controlled study 6-month open label study 
 Baseline Placebo GH pa GH pb 
IGF1 (nmol/L) 
(Reference range 7-32) 
11.5 ± 1.7 11.4 ± 1.3 32.9 ± 2.9 <0.0001 28.3 ± 2.0 <0.0001 
Body Composition 
LBM (kg) 
Fat mass (kg) 
 
44.6 ± 1.9 
29.5 ± 2.2 
 
44.4 ± 1.9 
29.8 ± 2.2 
 
45.3 ± 1.8 
29.2 ± 2.1 
 
NS 
NS 
 
45.2 ± 2.0 
28.0 ± 2.2 
 
0.06 
NS 
Physical performance 
Anaerobic Power (W) 
Anaerobic Power (W/kg LBM)  
VO2max (L/min) 
VO2max (mL/min/kg LBM) 
 
263 ± 17 
5.9 ± 0.2 
1.58 ± 0.1 
35.8 ± 1.4 
 
265 ± 16 
6.0 ± 0.3 
1.63 ± 0.1 
37.4 ± 1.8 
 
266 ± 17 
5.9 ± 0.2 
1.65 ± 0.1 
36.7 ± 1.5 
 
NS 
NS 
NS 
NS 
 
278 ± 16 
6.1 ± 0.2 
1.63 ± 0.1 
36.2 ± 1.5 
 
<0.05 
NS 
NS 
NS 
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Physical function 
Stair climb test (seconds) 
Chair stand test  
(Repetitions) 
 
Pedometry (Steps/day) 
 
 
20.0 ± 0.8 
 
19.5 ± 1.2 
 
 
6593 ± 563 
 
 
19.1 ± 0.7 
 
21.4 ± 1.2 
 
 
6295 ± 493 
 
 
18.8 ± 0.6 
 
21.7 ± 1.1 
 
 
6323 ± 595 
 
 
NS 
 
NS 
 
 
NS 
 
 
18.9 ± 0.7 
 
24.8 ± 1.2 
 
 
7780 ± 1044 
 
 
<0.01 
 
<0.0001 
 
 
<0.05 
 
Quality of life 
QoL-AGHDA score  
(out of 25) 
 
Energy and vitality score  
(out of 8) 
 
Non-energy and vitality score 
(out of 17) 
 
 
 
 
16.1 ± 1.6 
 
 
5.8 ± 0.6 
 
 
10.5 ± 1.1 
 
 
 
 
 
12.7 ± 1.8 
 
 
4.3 ± 0.7 
 
 
8.6 ± 1.2 
 
 
 
 
 
13.2 ± 1.6 
 
 
4.7 ± 0.7 
 
 
8.4 ± 1.1 
 
 
 
 
 
NS 
 
 
NS 
 
 
NS 
 
 
 
 
8.8 ± 1.4 
 
 
2.7 ± 0.6 
 
 
6.2 ± 1.0 
 
 
 
 
 
<0.001 
 
 
<0.001 
 
 
<0.01 
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4.4.2! Side effects 
 
There were no significant side effects observed during the placebo-controlled study that warranted 
any blinded-dose adjustment. 10 subjects reported side effects related to fluid retention including 
peripheral edema, joint stiffness, arthralgia and myalgia during the open label GH trial. These 
symptoms improved or resolved with a reduction in GH dose. One patient experienced significant 
peripheral edema and exacerbation of a preexisting carpal tunnel syndrome leading to withdrawal 
from the trial. 
 
 
4.4.3! 2-month placebo-controlled crossover study 
 
The data were analysed for carryover effects using a linear mixed model analysis. No significant 
carryover effects were identified in any outcome measures.  
 
 
4.4.3.1! Body composition (Table 4.2) 
 
There was no significant change in LBM or fat mass during placebo or GH treatment. (Figure 4.2, 
panel A and B).  
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Figure 4.2 Percent change from baseline in LBM (Panel A), fat mass (Panel B), anaerobic 
power (Panel C) and VO2max (Panel D) following 1 month of placebo and 1 month of GH 
(randomized controlled study), and 6 months of GH (open label study).  
LBM, lean body mass; VO2max, maximal oxygen consumption. ‘a’ indicates p < 0.05 vs. baseline; 
‘b’ indicates p < 0.05 vs. 1-month placebo treatment. 
 
 
4.4.3.2! Physical performance (Table 4.2) 
 
There was no significant change in anaerobic power during placebo or GH treatment (Figure 4.2, 
panel C). Similarly, no significant change in VO2max occurred during placebo or GH treatment 
(Figure 4.2, panel D). 
 
4.4.3.3! Physical function (Table 4.2) 
 
There was an equivalent mean reduction in stair climb duration during GH (p=0.03) and placebo 
(p=0.02) treatments (Figure 4.3, panel A). The number of chair stand repetitions increased 
significantly during GH (p=0.03) and placebo (p<0.05) treatments. However, the increase in chair 
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stand repetitions was not significantly different between GH and placebo treatments (Figure 4.3, 
panel B). Daily step count did not change significantly during placebo or GH treatments (Figure 
4.3, panel C). In summary, placebo effects were observed for stair climb and chair stand 
performance, which were similar to those observed during GH treatment. 
 
4.4.3.4! Quality of Life (Table 4.2) 
 
QoL-AGHDA score (Figure 4.3, panel D), energy and vitality score or non-energy and vitality 
score did not change significantly during placebo or GH treatment. 
 
 
Figure 4.3 Percent change from baseline in stair climb duration (Panel A), chair stand 
repetitions (Panel B), pedometry (Panel C), and QoL-AGHDA score (Panel D) following 1 
month of placebo and 1 month of GH (randomized controlled study), and 6 months of GH 
(open label study).  
‘a’ indicates p < 0.05 vs. baseline; ‘b’ indicates p < 0.05 vs. 1-month placebo treatment 
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4.4.4! 6-month open label GH study 
 
Because significant placebo effects occurred with some of the outcome measures (stair climb and 
chair stand performance), the effects of 6 months of GH therapy were compared with the change 
observed with placebo therapy during the double-blind phase. These effects were also compared 
with the baseline measurements. The results were similar except for stair climb duration, which 
improved significantly if a placebo effect was not accounted for.   
 
4.4.4.1! Body composition (Table 4.2) 
 
The mean LBM increased during 6 months of GH treatment with the change significantly greater 
than that observed after 1-month of placebo treatment (p=0.007) (Figure 4.2, panel A). FM fell 
during GH treatment, but the change did not reach statistical significance compared to that after 1-
month of placebo treatment (p=0.05) (Figure 4.2, panel B).  
 
4.4.4.2! Physical performance (Table 4.2) 
 
Mean anaerobic power increased at the end of 6 months of GH replacement (p<0.05). This increase 
was significantly greater than that observed after placebo treatment (p=0.04) (Figure 4.2, panel C).  
Increase in anaerobic power lost significance when corrected for changes in LBM (W/kg LBM). In 
contrast, the change in VO2max in absolute values (L/min) or corrected for LBM (mL/min/kg 
LBM) during 6 months of GH replacement was not significantly different from baseline or that 
observed after placebo treatment during the blinded phase (Figure 4.2, panel D). 
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4.4.4.3! Physical function (Table 4.2) 
 
The time to complete the stair climb test fell after 6 months of GH replacement (p<0.01). However, 
the reduction in stair climb duration was not significantly different from that observed after placebo 
treatment during the blinded phase (Figure 4.3, panel A). In the chair stand test, the number of 
repetitions performed in 30 seconds increased during 6 months of GH, a change that was 
significantly greater than that observed after placebo treatment (p<0.0001) (Figure 4.3, panel B). 
The average daily step count increased significantly after 6 months of GH replacement compared to 
that observed after placebo treatment (p=0.04) (Figure 4.3, panel C).  
 
4.4.4.4! Quality of Life (Table 4.2) 
 
Total QoL-AGHDA scores fell after 6 months of GH when compared to changes observed after 
placebo treatment during the blinded phase (p=0.04) (Figure 4.3, panel D). A sub-analysis revealed 
that scores for energy and vitality domains and for the non-energy and vitality related domains fell 
significantly (p<0.05) during GH treatment. 
 
4.4.5! Predictors of QoL  
 
 
The factors that significantly improved QoL during 6 months of GH replacement were identified 
using multiple regression analysis. This included age, gender, and improvements in LBM, 
anaerobic power, chair stand and stair climb performance, and daily step count as independent 
variables, the improvement in anaerobic power emerged as a significant predictor of the 
improvement in QoL energy and vitality scores (p=0.03) (table 4.3). However, none of the variables 
 102 
including anaerobic power was a significant independent predictor for overall QoL and non-energy 
and vitality related QoL domains. 
 
Table 4.3 Linear regression model of predictors of energy and vitality domains of QoL 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
 (Constant) 5.7 6.0  .95 .37 
Delta_LBM -.05 .31 -.05 -.17 .87 
Delta_anaerobic 
power -.07 .03 -.78 -2.7 .03 
Age -.01 .08 -.03 -.11 .92 
Gender  -4.6 2.5 -.63 -1.9 .09 
Delta_chair stand 
repetitions -.09 .18 -.13 -.51 .62 
Delta_daily steps .00 .00 -.23 -.94 .37 
a. Dependent Variable: Delta_energy and vitality scores 
 
 
4.5! Discussion 
 
This study investigated whether GH replacement improves anaerobic capacity, physical function 
and QoL in adults with GHD in a two-phase study comprising a 1-month double-blind placebo-
controlled phase followed by a 6-month open-label phase. During the blinded phase, GH did not 
improve any of the outcome measures compared to placebo, which induced significant 
improvements in stair climb and chair stand performance. In the open-label 6-month study, GH 
therapy significantly improved anaerobic power, chair stand performance, daily step count and QoL 
compared to placebo changes observed during the blinded phase. GH therapy did not improve 
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aerobic capacity. The increase in anaerobic capacity was significantly associated with improvement 
in energy and vitality QoL domains. 
 
A major aim was to determine whether GH improves anaerobic performance, which was assessed 
by the Wingate test. Anaerobic capacity is determined by energy availability and by contractile 
strength of muscle. To distinguish between these two mechanisms, the study was designed to assess 
the effects of GH treatment after 1 and 6 months. It was postulated that a mechanism enhancing 
energy provision would manifest early whereas that improving muscle strength through protein 
anabolism would take several months of therapy (197). This study found that anaerobic capacity did 
not change after 1 month but improved after 6 months of GH treatment. The loss of statistical 
significance in anaerobic capacity when corrected for changes in LBM, suggests that the improved 
anaerobic performance was in part due to increased LBM and muscle mass. These findings suggest 
that improvement in anaerobic capacity by GH may occur via an anabolic rather than a metabolic 
mechanism. 
 
The present finding that short-term GH treatment failed to improve anaerobic capacity in adults 
with GHD stand in contrast to a study in recreational athletes (8). In the latter study, short-term GH 
treatment significantly increased sprint capacity, which returned to baseline after cessation of 
treatment. The reasons for conflicting findings between the two studies are unclear but could arise 
from difference in dose, duration and subjects. The latter study was undertaken in GH replete 
recreational athletes who were administered a supraphysiological dose of 2 mg/day for 8 weeks. In 
contrast, the current study employed a daily dose of only 0.5mg for 4 weeks in subjects who were 
GH deficient. It is possible that the difference reflects the physiological and pharmacological effect 
of GH on the AES. 
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A second study aim was to determine the functional relevance of the anaerobic and aerobic energy 
systems. This was addressed by investigating whether a relationship is present between these 
energy systems and selected measures of daily activity. Activities such as rising from a chair or 
climbing stairs are supported mainly by the AES. Walking is a regular component of daily habitual 
activity. As walking consists of an initiation phase and a maintenance phase, both anaerobic and 
aerobic systems likely to contribute to daily walking capacity, which was estimated from weekly 
pedometry measurement. After 6 months of GH therapy, an improvement in anaerobic capacity was 
observed along with an improvement in chair stand performance and daily step counts.   There was 
no change observed in aerobic capacity with or without LBM correction. A likely reason that limits 
walking in patients with GHD is fatigue that develops quickly on initiation of physical activity 
because of subnormal anaerobic capacity. In real life, early fatigue may discourage the patient to 
continue further even though the physical activity of walking is far below the VO2max. There is a 
positive relationship between regular physical activity and health (198). Regular physical activity, 
including walking in healthy adults is associated with a reduction in coronary events (199), 
cerebrovascular events (200), cognitive dysfunction (201), and an improvement in health related 
QoL (202). Adults with hypopituitarism and GHD are an increased risk of premature cardiovascular 
mortality (6, 42). Thus, an improvement in daily habitual activity such as walking from GH 
replacement may have a beneficial long term impact on metabolic and cardiovascular health of 
adults with GHD. 
 
There was no significant improvement observed in aerobic capacity or body composition after GH 
replacement for up to 6 months. These findings stand in contrast with previous studies reporting an 
improvement in aerobic capacity (20, 21, 28, 37, 53, 133, 134, 197) and body composition (12, 20, 
32-34) in GHD after GH therapy. However, these studies employed much higher doses of GH 
compared to the current study dose. In a metaanalysis, Widdowson et al. observed that studies 
showing an improvement in aerobic capacity used a GH dose ranging between 0.86 and 2.2 mg per 
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day compared to 0.37mg per day in this study (203). Similarly, a separate metaanalysis of placebo-
controlled randomized trials found a clear dose response relationship for changes in LBM and fat 
mass (45). Hence, the modest changes in aerobic capacity and body composition are likely due to 
the lower doses of GH used in this study compared to the previous studies. 
 
A significant improvement in QoL was observed after 6 months of GH treatment in agreement with 
previous placebo-controlled studies (148, 149, 154, 157, 158). Further analysis revealed an 
improvement in the energy and vitality domain, which is the worst affected in GHD and exhibits the 
greatest improvement during GH replacement (153). The mechanisms explaining the impairment of 
QoL and its improvement after GH replacement are unclear. Although it seems reasonable to 
assume that anabolic effects of GH on muscle mass, and improvement in aerobic capacity may play 
a role in restoring QoL in adults with GHD, no correlation has been found between QoL and these 
parameters (6, 165, 166). It is conceivable that energy systems required to drive physical activity 
and function are likely factors influencing QoL. This study showed that during GH replacement, 
QoL improved in parallel with an improvement in anaerobic capacity, chair stand and daily walking 
capacity and in the absence of any improvement in aerobic capacity. Furthermore, within this global 
change, the improvement in the energy and vitality domains was independently influenced by 
anaerobic capacity. These results suggest that an improvement in the anaerobic but not the aerobic 
energy system underlies the improvement in energy and vitality during GH replacement, in turn 
facilitating physical activities such as rising from a chair and walking. 
 
This study has a number of limitations. The 6-month GH replacement study was not placebo-
controlled. This was address by comparing the outcome measures to those observed in response to 
placebo therapy in the 1-month blinded phase. It was a carefully planned study in the face of the 
feasibility and ethics of conducting a 6-month placebo-controlled trial for GH, already an approved 
replacement therapy for adults with GH deficiency involving daily injections. In planning this 
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study, a review of placebo-controlled GH trials was undertaken, in which functional (physical 
function and QoL) outcomes were measured on more than two occasions during the placebo arm. 
These trials showed that a placebo effect if present at the first evaluation does not change 
significantly on repeat evaluation (8, 148, 195). In these trials, the magnitude of change from the 
first evaluation during placebo phase to a later time point, usually after 3 to 6 months, was less than 
1.5%. The inclusion of a 1-month placebo controlled phase in this study allowed for the 
quantification of a placebo effect. Based on this evidence, the comparison of 6-month GH treatment 
outcomes with 1-month placebo measurements is valid and it was interpreted accordingly, but with 
some caution. This study was undertaken in a group of subjects who were predominantly women, 
who are less responsive to GH than men (13, 41). The higher female preponderance may have 
contributed to the modest changes observed in the outcome measures.  Because this study addresses 
the energy systems, it was investigated whether change in the energy system is accompanied by 
change in a health-related QoL domain that assesses energy-related symptoms. However, the use of 
subsections of the AGHDA questionnaire in this way requires further validation. 
 
This is the first study investigating the functional relevance of the AES in adults with GHD. 6 
months of GH replacement in adults with GHD increased anaerobic capacity, chair-stand 
performance, daily step counts and QoL but not aerobic capacity. Improvement in QoL occurred 
without an improvement in aerobic capacity during GH replacement. The improvement in anaerobic 
capacity independently predicted the improvement in energy and vitality of patients with GHD 
during GH replacement.  
 
In conclusion, GH replacement improves anaerobic capacity in a time-dependent manner. Chair 
stand and daily walking capacity are likely functional measures of the AES. Improvement in the 
anaerobic but not aerobic energy system explains in part the improvement in physical function and 
QoL in adults with GHD during GH replacement.  
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! EFFECTS OF GH ON METABOLIC GENE EXPRESSION IN 
SKELETAL MUSCLE 	 
 
5.1! Introduction 
 
The AES powers intense physical activity of brief duration as well as the initiation of all physical 
movement including activities of daily living (5). Thus, the AES plays a vital role in daily life. 
Impairment to the AES leads to early fatigue and loss of vitality, symptoms commonly experienced 
by adults with GHD (153).  
 
Early work from this thesis revealed that anaerobic capacity, the measure of AES, is impaired in 
adults with GHD compared to age, gender and BMI matched healthy adults (196). An intervention 
trial showed that GH replacement improves anaerobic capacity of adults with GHD in a time 
dependent manner (204). The mechanisms underlying the increase in anaerobic capacity following 
GH remain unclear. Anaerobic capacity depends on muscle mass and availability of energy to 
skeletal muscle. GH increases muscle mass in adults with GHD, but its effects on anaerobic energy 
metabolism in skeletal muscle are not known. 
 
GH is a major regulator of substrate metabolism and energy production. It increases plasma 
concentration of free FA by stimulating lipolysis (113-117), and glucose by stimulating 
gluconeogenesis and glycogenolysis (118, 119). GH effects on metabolism of these energy fuels 
have been extensively studied at a whole body level. The studies have shown that GH stimulates 
whole body FA oxidation and reduces glucose utilization in healthy adults (113, 120, 121) as well 
as adults with GHD (122-124). Because LBM accounts for the majority of substrate metabolism, it 
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is widely assumed that these effects reflect its action on skeletal muscle, however, the evidence to 
support this assumption is lacking.  
 
There is emerging evidence that GH action on substrate metabolism is tissue specific. Tollet-Egnell 
et al. reported that the effects of GH on liver and skeletal muscle in rodents may be disparate (126).  
In the liver, GH reduced expression of genes governing FA synthesis with an increase in genes for 
FA oxidation; where in muscle, genes for FA uptake were reduced and glycolysis were increased 
upon GH treatment. Similarly, in a small study of four adults with GHD, Sjogren at el. found that 
GH downregulated key genes governing lipid oxidation, TCA cycle activity and mitochondrial 
respiration as well as genes that suppress glucose utilization in skeletal muscle (7). These findings 
suggest that GH inhibits oxidative metabolism of substrates favoring non-oxidative glycolytic 
pathways for energy synthesis in skeletal muscle, opposite to that is seen at the whole body level. 
 
The aim of this study was to investigate whether GH alters the expression profiles of skeletal 
muscle genes in favour of anaerobic metabolism. This study was undertaken to identify 
differentially expressed genes involved in substrate metabolism in skeletal muscle following GH 
replacement in adults with GHD employing microarray technology. 
 
 
5.2! Material and Method 
 
5.2.1! Subjects 
 
10 out of 19 adults with GHD from the intervention trial described in chapter 4 participated in this 
study. The baseline characteristics, pituitary deficiencies and hormone replacements are 
summarized in chapter 4, Table 4.1 (Patient No. 2, 3, 4, 5, 6, 9, 10, 11, 13 and 19).    
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5.2.2! Study design 
 
10 adults with GHD underwent a 1-month double blind placebo controlled crossover study followed 
by 6-month open phase (Chapter 4). To understand the biochemical mechanisms underlying the 
improvement in anaerobic capacity, microarray experiments were performed to identify the 
differentially expressed genes in skeletal muscle after 1-month. These experiments were repeated 
after 6-month of GH treatment to investigate whether the short-term GH effects on metabolic gene 
expression are sustained with the continuation of GH treatment. 
 
Subjects attended the test venue after an overnight fast for a muscle biopsy of vastus lateralis after 
1-month of placebo and 1-month of GH treatment (placebo controlled phase), and at the end of 6-
month open label treatment with GH. Muscle samples collected during placebo treatment were 
considered as control samples. During the placebo-controlled study, GH (Norditropin; 
NovoNordisk, Denmark) replacement was initiated at a dose of 0.2mg/day for the first week, 
increased to 0.4 mg for the second week and to 0.5 mg, the target dose for the last two weeks. The 
gradual stepwise regimen was implemented to reduce side effects. During the open-label study, the 
GH dose was titrated individually to maintain serum IGFI concentrations in the age-adjusted adult 
normal reference range.  
 
Microarray experiments were performed and analyzed in two parts. The first part compared the 
gene expression in skeletal muscle in 6-subjects after 1-month of GH and placebo treatments 
(Patient No. 2, 3, 4, 5, 6 and 11; Chapter 4, Table 4.1). The second part compared gene expression 
in skeletal muscle after 1-month placebo with that after 6-month GH replacement in 9 subjects 
(Patient No. 2, 3, 4, 5, 9, 10, 11, 13 and 19; five out of nine patients participated in the 1-month 
study). The study was carried out in accordance with Good Clinical Practice guidelines, approved 
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by the Metro South Human Research Ethics Committee, and signed informed consent was obtained 
from all subjects. This study is registered in The Australian New Zealand Clinical Trials Registry 
(number: ACTRN12615000046505).  
 
 
5.2.3! Muscle biopsy 
 
Muscle biopsies were obtained using 5mm Bergstrom needle from vastus lateralis muscle as 
described in the Chapter 2. Using a suction technique, Bergstrom needle was used to yield 100-
150mg of muscle. Muscle tissue was immediately frozen in liquid nitrogen and stored at -80°C.  
 
 
5.2.4! RNA isolation 
 
Total RNA was isolated from snap-frozen muscle biopsies using the TRIzol Reagent (Life 
Technologies Inc., Gaithersburg, Maryland 20884, USA) during the placebo controlled study and 
RNeasy fibrous tissue extraction kit (Qiagen, Valencia, USA) during the open label study according 
to the manufacturer’s instructions as described in chapter 2 and stored at -80°C. The concentration 
of the RNA was assessed by NanoDrop spectrophotometer and the quality was determined using 
the Agilent RNA 6000 Nano Kit on the 2100 Bioanalyzer (Agilent, Amstelveen, The Netherlands). 
Only total RNA samples with a RNA integrity number (RIN) higher than seven were included for 
further analysis. 
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5.2.5! Microarray hybridization 
 
Microarray experiments were undertaken separately for the 1 month and 6 month studies. Samples 
for the 1-month study were processed at the Australian Genome Research Facility (Melbourne, 
Australia) and for the 6-month study at the University of Queensland Diamantina Institute 
(Brisbane, Australia). For both experiments, the RNA samples were biotinylated and amplified 
using the Illumina® TotalPrep™ RNA Amplification Kit (Ambion, Austin, TX, USA) according to 
the manufacturer’s instructions with a standardized input amount of 500ng. 
 
Briefly, the procedure consists of reverse transcription of total RNA to first strand cDNA, which 
then undergoes second strand synthesis and purification to become a template for transcription. In 
vitro transcription of dsDNA was used to synthesize cRNA labelled with biotin-16-uridine-5-
triphosphate (UTP). The labelled probes were hybridized to Illumina HumanHT-12 v4 microarrays 
(San Diego, CA) including approximately 47,000 probes as per manufacturer’s instructions and 
whole-genome transcriptional profiling was performed. The beadchips were scanned using Illumina 
BeadStation, and the signal was extracted by using Illumina BeadStudio software. 
 
5.2.6! qRT-PCR verification 
 
Reverse transcription PCR was performed to validate the microarray findings using SuperScript III 
First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). Synthesized cDNA was used for 
real-time quantitative PCR, which  was performed in triplicate on a ViiATM Real Time PCR System 
(Applied Biosystems, Foster City, CA) using TaqMan Gene Expression assays (Applied 
Biosystems), with the assay IDs as follows: Fatty acid synthase (FASN) (Hs01005622_ml), 
Stearoyl-CoA desaturase 1 (SCD) (Hs01682761_ml), Dual specificity phosphatase 1 (DUSP1) 
(Hs00610256_ml), G0/G1 switch 2 (G0S2) (Hs00274783_ml), 3-hydroxy-3-methylglutaryl-CoA 
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synthase 2 (HMGCS2) (Hs00985427_ml)), Uncoupling protein 3 (UCP3) (Hs01106052_ml), Beta-
2-microglobulin (B2M) (Hs00187842_ml). Relative mRNA levels were calculated by the 
comparative threshold cycle method using B2M as the housekeeping gene.  
 
5.3! Bioinformatics and statistical analysis 
 
The data were analyzed using statistical programming language R and quality control steps were 
performed using Bioconductor packages lumi (205) and limma (206). To correct the variation 
between the Genechips, Microarray data of .idat files of Illumina beadchips were log2 transformed 
and normalized using quantile normalization. The unsupervised technique principal component 
analysis (PCA) multilevel was used to explore the data and identify a potential natural separation 
between patients before and after treatment as well as potential confounder effects. After 
logarithmic transformation, the results for baseline samples and GH treated samples (1-month and 
6-month) were analyzed using paired t-test. The P value was adjusted for multiple testing, using the 
Benjamini and Hochberg method (207) set at a  false discovery rate (FDR) of 5%. A gene was 
considered regulated if there was a fold change of ≥1.4 or ≤0.7 in response to GH, criteria similar to 
those previously published (7). Because the GHD patients were treated with a physiological 
replacement dose of GH, only a modest effect on gene expression was expected. qRT-PCR method 
was used to validate the microarray results. 
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5.4! Results 
 
5.4.1! IGFI concentration  
 
Mean IGFI concentration rose significantly in response to GH administration during the placebo-
controlled (p<0.01) and open phase (p<0.0001) (Figure 5.1). During the open phase, the GH dose 
was titrated to maintain the IGF-I concentration in the adult normal range (9 to 33 nmol/L), 
resulting in a reduction of the mean GH dose from 0.5 to 0.43 mg/day. 
 
 
 
Figure 5.1 Mean IGF concentration during 1-month placebo controlled study (Panel A) and 6-
month open label study (Panel B) in six and nine adults with GHD respectively.  
‘a’ indicates p < 0.01 vs. placebo, ‘b’ indicates p < 0.01 vs. baseline; ‘c’ indicates p < 0.0001 vs. 
baseline. 
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5.4.2! Effect of GH on gene expression 
 
 
5.4.2.1! Effect of 1-month of GH 
 
 
1-month GH replacement did not induce any significant changes in gene expression in skeletal 
muscle of adults with GHD at an FDR of 5%. When data were reanalyzed using an unadjusted P 
value without setting an FDR threshold, no differentially expressed genes were identified compared 
to the control samples. As described in Chapter 4, no significant changes in aerobic or anaerobic 
capacity were observed between GH and placebo treatments. 
 
5.4.2.2! Effect of 6-month of GH 
 
 
A significant improvement occurred in anaerobic capacity after six months of GH replacement. No 
significant changes in gene expression of skeletal muscle were detected at an FDR of 5%. However, 
when an unadjusted P value was used, 14 differentially expressed genes were identified. Amongst 
these genes, 10 were upregulated and 4 downregulated (Table 5.1). The relationship between P 
value and log fold change for all probes is represented by a volcano plot in figure 5.2, showing the 
14 differentially expressed genes using an unadjusted P value of 0.05 (horizontal orange line) and 
the fold change of 0.7 and 1.4 by vertical green and red lines respectively.  
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Table 5.1 GH responsive genes in skeletal muscle 
 
Gene title Gene symbol Fold change* p value 
Upregulated genes    
Fatty acid synthase  FASN 1.5 0.04 
Stearoyl-CoA desaturase 1 (delta-9-
desaturase)  
SCD1 1.8 0.04 
Dual specificity phosphatase 1  DUSP1 1.5 0.01 
G0/G1 switch 2 G0S2 1.9 0.0002 
Interleukin 32 IL32 1.5 0.0001 
Early growth response 1 EGR1 1.9 0.0005 
FBJ murine osteosarcoma viral oncogene 
homolog 
 
FOS 2.0 0.002 
Cysteine-rich, angiogenic inducer 61 CYR61 1.4 0.008 
Regulator of calcineurin 1 RCAN1 1.6 0.01 
Transferrin receptor TFRC 1.4 0.01 
Downregulated genes    
3-hydroxy-3-methylglutaryl-CoA synthase 
2 (mitochondrial)  
HMGCS2  0.7 0.03 
Uncoupling protein 3 (mitochondrial) UCP3 0.7 0.002 
Metallothionein 2A  MT2A 0.7 0.004 
Tetraspanin 8 TSPAN8 0.7 <0.0001 
*6-month GH-treated relative to baseline samples 
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Figure 5.2 Relationship between p value and log fold change for all probes on microarray in 9 
GH treated subjects at 6 months.  
The horizontal line represents threshold p value of <0.05, whereas vertical lines indicate log2 fold 
change of 0.45. 
 
 
 
 
5.4.3! Verification of Microarray results 
 
To verify the microarray data, the transcript levels of six genes that play a major role in substrate 
metabolism (FASN, SCD1, DUSP1, G0S2, HMGCS2 and UCP3) were quantified by qRT-PCR. 
Analysis was performed on individual samples, with B2M included as an internal control. As 
shown in Figure 5.3, none of the transcripts quantified by qRT-PCR changed significantly during 
GH treatment.  
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Figure 5.3 qRT-PCR verification of six GH responsive genes.  
Results are relative mRNA expression adjusted for the expression of B2M of baseline and 6-month 
GH treated samples. There was no significant change observed in the expression of any of these six 
genes after 6-month of GH treatment. 
 
 
 
5.5! Discussion 
 
This study investigated GH effects on the AES by studying the gene expression profile of skeletal 
muscle from adults with GHD in a two-phase study comprising a 1-month double-blind placebo-
controlled phase followed by a 6-month open-label phase. During GH treatment, serum IGFI 
concentrations increased into the normal adult range. Neither one month or six months of GH 
replacement induced any significant change in expression of genes governing energy metabolism in 
skeletal muscle of adults with GHD.  
 
These results stand in contrast with previous studies in rodents as well as in human adults with 
GHD, which provided evidence that GH suppresses oxidative metabolism in muscle and favours 
non-oxidative energy production via glycolysis (7, 126). Tollet-Egnell et al. reported that GH 
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uptake in skeletal muscle of rats (126). Sjogren et al. reported that GH suppressed genes governing 
lipid oxidation, TCA cycle activity and mitochondrial respiration as well as genes that suppress 
glucose utilization in skeletal muscle of adults with GHD (7). Expression of genes involved in FA 
transport such as fatty acid binding protein-3 (FABP-3) and CTP-I fell by 50%. Genes for several 
enzymes that mediate β-oxidation of FA and ATP synthesis via oxidative pathway in the 
mitochondria were also suppressed in skeletal muscle following GH therapy. For example, the 
expression of oxoglutarate dehydrogenase and succinate dehydrogenase complex B in the TCA 
cycle and ATP synthase and NADH dehydrogenase in the mitochondrial respiratory chain were 
reduced by up to 40%. GH also reduced the transcripts levels of pyruvate dehydrogenase kinase-4 
(PDK-4) and glycogen synthase-I in muscle. The latter has been reported in previous studies in 
healthy (127) as well as adults with GHD (128). PDK-4 is an inhibitor PDH, the key enzyme that 
converts pyruvate to Acetyl CoA for oxidation in mitochondria (129). These findings validated by 
qRT-PCR indicate that GH favours glucose as a metabolic fuel over lipid in skeletal muscle. 
 
The reasons for discrepant findings between the current study and that of Sjogren et al. are unclear. 
The current study used a dose of GH (0.5mg/ day) similar to the Sjogren study. A key difference 
between the two studies is the gender of subjects. The study by Sjogren et al. was undertaken in 4 
men with GHD, as compared to women in the current study. Women with GHD are less responsive 
to GH  as compared to men and require a higher replacement dose of GH than men (208-210). 
Testosterone enhances the anabolic responses to GH. Testosterone co administered with GH result 
in a significantly higher IGFI levels and rate of whole body protein synthesis compared with GH 
alone (8, 122). Thus, GH effects in the Sjogren study may have been more pronounced due to the 
concomitant administration of testosterone, and a higher dose of GH may be required to achieve 
similar effects in women. 
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Other explanation for the lack of significant change in gene expression to GH may be technical. 
Methodological issues may stem from quality of RNA, the amount of RNA included in the RNA 
labeling reaction, differences in efficiency of the biochemical transformations, and steps within the 
RNA labelling itself including reverse transcription, dye incorporation and fluorescent label 
detection. However, each sample was carefully assessed by a Bioanalyser and only the samples 
with a RIN above 7 were included in the experiments to ensure good quality of RNA. Robust 
quality control analyses were undertaken for the normalization of raw microarray data using the 
appropriate statistical software to control for other non-biological variations. 
 
Subjects received a small physiological replacement dose of GH and hence only a modest change in 
gene expression was expected. In constraining false positives, setting a FDR at 5% may have been 
too stringent for detecting small effect of GH. When a FDR was not set at all, 14 differentially 
expressed genes were identified based on the ranking by fold change. Eight of these genes 
(RCAN1, EGR1, FOS, TFRC, CYR61, IL32, MT2A, TSPAN8) are involved in growth, cell 
proliferation and differentiation, apoptosis and inflammation, but their role in skeletal muscle 
substrate metabolism is unknown. The remaining six genes are known to play a significant role in 
substrate metabolism, 4 of which were upregulated (FASN, SCD1, DUSP1 and G0S2) and 2 
downregulated (HMGCS2 and UCP3). 
 
Among the upregulated genes, FASN is a GH-regulated gene that stimulates FA synthesis in 
adipose tissue and liver. Reduction in FASN expression in adipose tissue and liver leads to 
increased lipid oxidation (211, 212). Increased FASN expression in adipose tissue increases 
lipogenesis (213). Hence, it is conceivable that increased expression of FASN in muscle is also 
likely to increase lipogenesis and reduce lipid oxidation. SCD1 catalyzes the final rate-limiting step 
in de novo lipogenesis. SCD1 knock out mice manifest an increase in FA oxidation in liver, muscle 
and brown adipose tissue and a reduction in de novo lipid synthesis (214, 215), suggesting GH 
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induced increase in SCD1 expression is likely to inhibit lipid oxidation in muscle. DUSP1 is a key 
regulator of PGC1α. PGC1α drives mitochondrial biogenesis and function in skeletal muscle and 
maintains oxidative fibre type distribution (216, 217). DUSP1 overexpression leads to reduction in 
mitochondrial phosphorylation, lipid oxidation and proportion of oxidative fires in skeletal muscle 
(216, 218). G0S2 inhibits adipose triglyceride lipase, a rate-limiting enzyme in lipolysis, and causes 
reduction in lipid oxidation and increase in glucose uptake in skeletal muscle (219). Among the 
downregulated genes, HMGCS2 is an important enzyme in ketone body formation and reduction of 
this enzyme leads to an increase in glucose utilization for ATP synthesis (220, 221). Suppression of 
UCP3 expression causes a reduction in lipid oxidation in skeletal muscle (222). Collectively these 
results indicate that GH reduces lipid oxidation and mitochondrial function, and increases glucose 
utilization for ATP synthesis in skeletal muscle. However, these results could not be validated by 
qRT-PCR. 
 
Apart from the availability of anaerobic energy, anaerobic capacity also depends on anabolic 
properties of skeletal muscle including muscle mass, strength and the proportion of fast twitch type 
II muscle fibres that determines the contractile force of muscle (5, 223). In this study, GH treatment 
did not significantly change the expression of genes involved in the regulation of muscle anabolism 
or fibre type distribution such as muscle IGFI receptor (IGFIR), myogenic differentiation 1 
(MYOD1), myostatin (MSTN) and myosin heavy chain isoforms (MYH1, MYH 2).  
 
In summary, GH replacement in a group of predominantly female patients with GHD was 
associated with minor changes in metabolic gene expression that failed to reach statistical 
significance and validation by qRT-PCR. In conclusion, studies with a larger sample size with a 
balanced gender distribution are required to identify the GH-responsive genes that underlie the 
regulation of anaerobic energy metabolism in skeletal muscle. 
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6! SUMMARY AND CONCLUSIONS 
 
6.1! Introduction 
  
This thesis investigated the role of GH in the regulation of the AES. The first aim was to investigate 
whether anaerobic capacity is impaired in adults with GHD and if so, its functional significance. 
This was assessed in a cross-sectional comparison of anaerobic capacity, physical function and QoL 
between adults with GHD and matched healthy controls, and reported in Chapter 3. 
 
The second aim was to investigate whether GH replacement improves anaerobic capacity in adults 
with GHD and whether this is associated with changes in physical function and in QoL. Described 
in Chapter 4, this was addressed by a 1-month double-blind placebo controlled crossover study, 
followed by a 6-month open-label active treatment phase. 
 
The third aim was to evaluate the effects of GH on anaerobic substrate metabolism in skeletal 
muscle of adults with GHD. Reported in the chapter 5, this was assessed by studying the changes in 
metabolic gene expression in muscle biopsy tissue obtained after 1-month and 6-month of GH 
treatment. 
 
The methods used for this body of work, described in Chapter 2 included physical performance 
tests, physical function tests, body composition measurement, QoL assessment, RNA isolation, 
gene expression profiling using microarray technology and qRT-PCR. Anaerobic capacity was 
assessed by the Wingate test, and aerobic capacity by the VO2max test. Physical function was 
assessed by the stair-climb test, chair-stand test, and 7-day pedometry. QoL was assessed by a 
GHD-specific questionnaire. The reproducibility of the physical performance and function tests 
were established by studying 5 healthy volunteers on two separate occasions. The microarray 
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experiments were performed at AGRF, Melbourne, Australia (1-month placebo controlled study) 
and UQ Diamantina Institute, Brisbane, Australia (6-month open-label study). 
 
6.2! Summary and conclusions 
 
The cross-sectional study showed that anaerobic power was nearly 20% lower in adults with GHD 
compared to control subjects, a deficit similar to that observed for VO2max. Stair climb capability, 
chair stand performance and daily step counts, measures of physical performance were significantly 
impaired as was QoL. GH status of the subjects was an independent determinant of anaerobic 
capacity. Anaerobic capacity independently predicted stair climb performance and QoL. 
 
One-month of GH replacement did not improve any of the outcome measures compared to placebo 
treatment. Six months of GH replacement increased anaerobic capacity, LBM, chair-stand 
performance, daily step count and QoL, but not aerobic capacity compared to baseline and to 
changes observed during placebo treatment for 1-month. QoL improved without a corresponding 
improvement in aerobic capacity. The improvement in anaerobic capacity independently predicted 
the improvement in energy and vitality domains of QoL in adults with GHD.  
 
GH replacement was associated with minor changes in some metabolic genes in skeletal muscle 
that did not reach statistical significance and failed validation by qRT-PCR. 
 
In conclusion, GH regulates the AES. In adults, a lack of GH impairs anaerobic capacity, adversely 
affecting physical function and QoL. GH replacement improves anaerobic capacity in a time-
dependent manner. Chair stand and daily walking capacity are likely functional indicators of the 
anaerobic energy system. Improvement in the anaerobic but not aerobic energy system explains in 
part the improvement in physical function and QoL in adults with GHD during GH replacement. 
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The molecular and cellular mechanisms underlying GH mediated stimulation of the AES in skeletal 
muscle remain unclear. 
 
6.3! Future directions 
 
This body of work provides the first evidence for a regulatory role of GH on muscle function 
dependent on the AES and its functional relevance to daily living by studying adults with GHD. 
The work tested the hypothesis that GH replacement improves anaerobic capacity within a few 
weeks and this effect is sustained. However, GH improved anaerobic capacity only after six months 
of treatment without significant changes in metabolic gene expression in skeletal muscle. These 
findings stand in contract to a previous study in recreational athletes showing an enhancement of 
anaerobic capacity after 8 weeks (8) and a study in a small group of GH-deficient males reporting a 
significant change in metabolic gene expression in muscle after only 2 weeks of GH treatment (7). 
The reason for discrepant findings between the current and latter study (7) despite using the same 
dose and similar treatment duration is likely the gender of participants who were entirely women in 
the current study and men in the latter study. The preponderance of females in the current study 
arose by chance and the difficulty encountered in recruiting equal numbers of male participants 
with GHD. Women with GHD are less responsive to GH and require a higher replacement dose of 
GH than men (208-210). Hence, a larger sample size may be required to show a similar effect in a 
study involving only women. Although Meinhardt et al. (8) reported an improvement in anaerobic 
capacity in a pooled group of normal women and men after eight weeks of GH treatment, no 
significant effect occurred in women alone despite a 4 times higher GH dose used in this trial, again 
emphasizing gender-specific differences in GH sensitivity. The improvement in anaerobic capacity 
at 6 months in the current study likely arose from an anabolic effect on muscle mass and strength 
that occurs after long-term GH therapy (32, 49, 50, 61). To minimize sample size, future studies to 
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identify GH-regulated metabolic genes in skeletal muscle that improve anaerobic capacity should 
be undertaken using a similar replacement dose in men with GHD. 
 
Microarray is a powerful research method that allows the study of expression patterns of tens of 
thousands of genes in a tissue sample. However, the results are based on an assumption that 
transcriptional changes reflect the effects on protein expression. Future studies investigating GH 
effects on substrate metabolism in skeletal muscle should also assess the changes in enzyme 
activities governing anaerobic and aerobic metabolism by analyzing protein expression by Western 
Blot or quantify biochemical pathway changes of glycolysis. The feasibility of such studies in 
humans is difficult due to the invasive procedure and large amount of tissue sample requirement. 
Such studies investigating tissue enzyme and biochemical changes should be conducted in animals.  
 
The mechanisms underlying the impairment in QoL and its improvement after GH replacement in 
adults with GHD are poorly understood. Previous studies have not found any relationship between 
QoL and changes in aerobic capacity or other anabolic parameters during GH replacement therapy. 
Future studies should explore further the role the AES in influencing QoL in adults with GHD using 
validated research tools specifically designed to assess energy and vitality domains of QoL, such as 
Nottingham Health Profile questionnaire and Well-being Questionnaire 12 (224, 225). 
 
The age-related decline in physical and function capacity has been attributed to a progressive fall in 
GH secretion with advancing age. Several well conducted GH trials have not observed any 
beneficial physical outcomes leading to considerable doubt as to the value in GH supplementation 
for older people (70, 71, 195, 226-228). However, these trials have focused on GH effects on 
muscle strength and aerobic capacity. None has assessed effects on the AES and related functional 
measures. A study investigating the effects of capromorelin a GH secretagogue, reported an 
improvement in tandem walk test and power stair climb test (195); both these tests assess  the first 
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10-30 seconds of physical exertion, that is predominantly powered by the AES. The authors did not 
link this improvement in physical function to the AES or assessed its impact on QoL or on 
functional aspects of daily living. The current study provided strong evidence that daily walking 
capacity is a function of the AES, which improved after GH treatment. Daily walking capacity is 
associated with better cardiovascular outcomes, cognitive function and health related QoL in older 
adults (200-202). The findings of the current study call for a reassessment of GH supplementation 
on physical function relevant to the AES in older adults. This can be assessed by pedometry, Timed 
Up and Go test and Gait Speed measurement, and correlating these with the changes in their energy 
and vitality domains of QoL (179, 229). The Timed Up and Go test is a useful predictor of risk of 
falls in frail elderly (230), a cause of significant morbidity in this population. An improvement in 
gait speed predicts a significant reduction morbidity such as disability, institutionalization, falls, and 
mortality in older people (231, 232). A similar approach should be used to investigate whether GH 
accelerates physical mobilization and rehabilitation after major surgery or trauma by stimulating 
anaerobic capacity 
 
The AES is an ignored area of fitness research, which has focused heavily on aerobic capacity. This 
body of work provides the first evidence for the hormonal regulation of the AES and its relevance 
in daily life. This information can be exploited in designing future research trials combating frailty 
associated with chronic diseases and ageing. 
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